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ABSTRACT 
Alhamdan, Nasser. M.S., Microbiology and Immunology Graduate Program. Wright 
State University, 2017. Genomic vs. Non-genomic Role of the AhR in Human 
Immunoglobulin Expression. 
 The immunoglobulin heavy chain gene (Igh) in various animal models is regulated 
by numerous regulatory elements including the 3’Igh regulatory region (3’IghRR). Several 
transcription factors are involved in modulating the 3’IghRR including the aryl 
hydrocarbon receptor (AhR). The AhR is a ligand-activated transcription factor that 
mediates the transcription of genes involved in the metabolism of environmental toxicants 
such as TCDD. TCDD binds AhR and regulates immunoglobulin (Ig) expression in B cells. 
This modulation appears to be directly mediated by binding of the AhR to dioxin response 
elements (DRE) within the 3’IghRR.  In human B cells, IgG secretion inhibited by TCDD 
and increased by chemical antagonist of the AhR (AhRA). AhR can interact with different 
transcription factors like NFκB and AP-1, and modulate signaling pathways such as Src 
and Akt pathways. the human CL-01 cells express a nonfunctional transactivation domain 
(AhR TA) in one of its alleles. Therefore, we hypothesized that in human cells the AhR 
regulates IGH expression by altering 3’IGHRR activation through both genomic and non-
genomic mediated mechanisms. The current study focuses on determining the potential 
non-genomic effects of the AhR on the activation of cytosolic signaling proteins such as 
Src and Akt, and transcription factors like NFκB and AP-1. In addition, it evaluates the 
genomic effects of the nonfunctional AhR TA on the 3’IGHRR reporter activity and 
evaluates the role of AhR in the effect of the TCDD and AhRA on Ig expressing and 
3’IGHRR activity. Our results showed that the AhR has non-genomic effects by activating 
cytosolic signaling protein like Akt and increasing the Iγ3-3’IGHRR reporter activity in 
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response to AhRA that could lead to an increase in IgG secretion. The nonfunctional AhR 
TA decreased the AhR binding to DRE sites as demonstrated in a DRE reporter but it did 
not affect 3’IGHRR activity in response to TCDD or AhRA. AhR knockdown by gene 
editing demonstrated inhibition of IgG secretion and AhRA had no effect on Iγ3-3’IGHRR 
activity, supporting the suggested a physiological non-genomic role of the AhR in the 
expression of IgG. Determining the role of the 3’IGHRR and its potential difference in 
sensitivity to the AhR could provide new insight into potential environmental triggers of 
immune disorders and provide new targets for drug development. 
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I. INTRODUCTION 
The immune system 
 The immune system is a host defense system that consists of a cooperative network 
between cells, organs and tissues to protect the body. This network has mechanisms that 
identify and neutralize different threats to the human body. Threats can be arise from 
harmful alterations happening inside the body such as dysregulation of a normal cell into 
a tumor cell or that may enter the body from the outside such as infectious bacteria or toxic 
agents. The immune system has the ability to differentiate self-organisms and molecules 
from nonself and contains two lines of defense against threats. The first line is the innate 
immune system that include a group of well-maintained chemical, mechanical and 
microbiological barriers that prevent pathogens from entering the body. In the event that 
these barriers are penetrated, the nonspecific components of the innate immune system, 
then the second line, which is the specific adaptive immune system, are activated (Parham, 
2009). 
 Each defense system has special recognizing mechanisms that has advantages and 
disadvantages. The mechanisms of innate immune system are ready for action. It has fast 
response that just takes a few hours to distinguish pathogens. Some of the innate immunity 
mechanisms are constantly work even if there is no pathogen, for example antimicrobial 
proteins continuously secreted into gut. This system is non-specific because it responds the 
same to a variety of antigens and it attacks all pathogens equally. The core components of 
innate immunity include macrophages, neutrophils and natural killer cells. Once the 
pathogen invades the body, the innate effector cells recognize pathogen-associated 
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molecular patterns (PAMPs) through pattern recognition receptors (PRR) expressed on the 
surface of innate effector cells. Pathogen recognition induces innate effector cells to secrete 
inflammatory mediators such as cytokines and chemokines. In contrast, the adaptive 
immune system has slower reactions and it may takes days or even weeks to recognize 
antigens and support an immune response, but antigens are selected by highly specificity. 
The adaptive immunity generates an immune response by antibody-mediated immunity or 
cell- mediated immunity as well as immunological memory, which gives the host long-
term protection from reinfection by the same specific pathogen (Parham, 2009). Innate and 
adaptive immunity cooperate by a lot of cross-reaction between the two mechanisms. For 
example, some of the innate system cells are critical for activation of the adaptive system 
cells and can in turn have their activity elevated and directed by activated cells from the 
adaptive system (Doan, et.al, 2008). 
 The adaptive immune system has unique cells and molecules. It is the second level 
of defense against potential threats to the body, following the barriers and the innate 
immune system. It can eliminate specific antigens by either cell-mediated immunity or 
antibody-mediated (humoral) immunity. Cell-mediated immunity is dominated by T cells 
that bind to antigens presented on the cell surface via major histocompatibility complex 
(MHC). T cells express CD4+ (T helper) that bind to antigens presented by MHC molecules 
class II (MHC II). These molecules are exclusively expressed on antigen-presenting cells, 
which include macrophages, dendritic cells, and B-cells. Binding of CD4+ T-helper cells 
with (MHC II) molecules leads to proliferation and differentiation of the T-helper cells into 
memory, effector or regulatory T helper cells. Moreover, T cells expressing CD8 (cytotoxic 
T cells) bind to an antigen presented by MHC class I, which is expressed by nearly all 
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nucleated cells of the body. Cytotoxic T-cells are specialized to recognize and fight cancer 
cells and intracellular infection by destroying cells presenting foreign intracellular antigen 
in their MHC I. On the other hand, antibody-mediated immunity is mediated by B cells 
that differentiate into antibody-forming cells (plasma cells), which produce specific 
antibodies against a particular epitope: the part of an antigen that is recognized by 
antibodies (Parham, 2005).  
B cells 
 B cells are the main effectors of the antibody-mediated response of adaptive 
immunity. Like other cells, B cells are created in the bone marrow and then circulate as 
immature or mature B cells through blood and lymph nodes to the secondary lymphoid 
tissue like the spleen. B cells have transmembrane proteins called B-cell receptor (BCR) 
located on the surface of B cells. Each BCR has only one isotype of a membrane-bound 
immunoglobulin (Ig), and all isotypes on the same B cell have the same antigen-binding 
site. Mature B cells that express IgM and IgD on their surface and have not been exposed 
to antigens are called naïve. They circulate in the bloodstream and lymph as inactive B 
cells, and once they recognize specific antigens, they become activated and differentiate 
into antibody-secreting cells (plasma cells). 
 In order to activate B cells, a signal provided by antigen and interaction with helper 
T cells stimulates B cells to proliferate and differentiate into plasma cells or long-lived 
memory B cells. Plasma cells secrete a huge amount of antibodies, the soluble form of Ig, 
in response to antigen and release them into the circulation. The amount of antibodies 
production decrease as the stimulus of infection is removed by the elimination of the 
pathogen from the body. The antibodies can be present in the circulation for several months 
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afterward. The IgM antibody isotype mediates the primary immune response when mature 
B cells encounter antigen for the first time and differentiate to produce memory cells (long-
lived cells) and plasma cells. On the other hand, the secondary immune response mediated 
when memory B cells are re-expose to the same antigen, is a faster immune response and 
these cells produce a huge amount of specific and high-affinity antibodies of different 
isotypes such as IgG. 
Immunoglobulins  
 Ig proteins are the critical ingredients at every stage of the humoral acquired 
immune response. Antibodies are the Ig that are secreted from B cells and travel through 
the circulation to bind to the specific antigens that triggered their production (Parslow et.al, 
2001). Ig contains four polypeptides chains: two identical light chains (IgL) and two 
identical heavy chains (IgH) linked by disulfide bonds to form a monomeric subunit (Fig. 
1).  The antigen-binding site (epitope-binding site) at the tip of the arm is formed by a 
single heavy chain and a single light chain. A single antibody subunit is bivalent due to the 
two arms, which have identical antigen-binding sites. Each chain has a C-terminal end with 
a constant amino acid sequence (constant region) and an N-terminal end with a variable 
amino acid sequence (variable region), which is responsible for the huge diversity of the 
antigen binding site. Heavy chains contain one variable (VH) domain and three or four 
constant (CH) domains (Fig. 1). There are five isotypes of Ig (IgM, IgD, IgG, IgE and IgA), 
each isotype is encoded by a specific constant region within the Ig heavy chain gene: Cμ, 
Cδ, Cγ, Cε, and Cα are encoded for isotypes IgM, IgD, IgG, IgE, and IgA respectively. In 
human, there are four IgG subclasses IgG1, IgG2, IgG3 and IgG4 encoded by Cγ1, Cγ2, 
Cγ3 and Cγ4 heavy chain genes, respectively and two IgA subclasses IgA1 and IgA2 
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encoded by Cα1 and Cα2 heavy chain genes, respectively. Normally, humans produce two 
types of light chain, kappa (κ) or lambda (λ). Light chains contain one variable (VL) domain 
and one constant (CL) domain. In an individual B cell, each Ig monomer contains two 
identical kappa (κ) or two identical lambda (λ) but never both (Doan, et.al, 2008).  
 The IgM isotype is the first Ig formed and is found as a monomer on the B-cell 
surface. Once B cells differentiate into plasma cell, IgM is secreted as a pentamer resulting 
in a total of 10 antigen-binding sites. IgM is the primary antibody secreted in a primary 
response. As the response progresses somatic hypermutation and class switch 
recombination are engaged, which will result in a change in the antibody isotype and in the 
immune response according to the type of encountered antigen. 
 The IgD isotype has a monomeric structure and is mostly displayed on the B-cell 
surface. It works as a co-receptor along with IgM and it can activate basophils and mast 
cells to coordinate an immune response that eliminates bacteria (Parham, 2005). 
 The IgG isotypes (IgG1-4) are secreted as monomers and they are the most 
abundant antibody in the serum. IgG is produced by B cells in a huge amount during a 
secondary immune response and it is the only Ig isotype that can cross the placental barrier 
to give immunity to the fetus. It can activate complement, and neutralize microorganism 
and viruses (Doan, et.al, 2008). 
 The IgA isotypes (IgA1-2) are the main antibody found in body secretions. IgA can 
be secreted as a monomer as found in the serum or as a dimer as found in secretions, 
including milk, saliva, sweat, tears, and intestinal secretions. IgA provides protection 
against microbes in body secretions. 
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 The IgE isotype is secreted as a monomer and binds to mast cells, eosinophils, and 
basophiles in the absence of antigen. When antigen binds to IgE on eosinophil, a strong 
physical reaction and inflammatory reaction is triggered to kill parasites, while IgE on mast 
cells and basophils triggers the release of histamine leading to immediate hypersensitivity 
responses (Doan, et.al, 2008). 
 Somatic recombination or VDJ recombination happen during early B lymphocyte 
development in the bone marrow to form the antigen-binding sites. It is assembly of the 
variable (V), diversity (D) and joining (J) gene segments that gives rise to the variable 
region exons of the antigen receptor. The V and J gene segments encode the light chain 
variable region (VL), while the heavy chain variable region (VH) also has the D segments 
along with V and J. VDJ recombination needs recombination activating genes 1 and 2 
(RAG-1 and RAG-2) to complete this process. In the heavy chain (VH), random D and J 
gene segments recombine together and the intervening DNA sequences between them are 
deleted. Eventually, the D-J recombination is joined to a V gene segment to get a 
rearranged VDJ gene segment. In the light chain variable region (VL), only one 
recombination V to J takes place. V(D)J recombination helps to produce high diversity of 
antigen binding sites. When mature B cells interact with antigen, they undergo two more 
forms of genetic change within the Ig genes: somatic hypermutation (SHM) and isotype 
class switch recombination (CSR). In somatic hypermutation, point mutations are induced 
within the DNA sequences of the heavy and light chain variable regions with the aim of 
increasing Ig affinity for a particular antigen. Class switch recombination refers to isotype 
switching from IgM to IgG, IgE or IgA isotypes. CSR occurs only in the heavy chain 
constant region (CH) by joining the rearranged variable region exon to a different 
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downstream constant region (i.e. Cγ1-4, Cε, or Cα1-2), and delete the intervening germline 
DNA. These events enable a rearranged V-region to be used with other heavy chain C-
regions in order to express different antibody isotypes with the same antigen specificity 
(Parham, 2005).  
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Figure 1. Structure of Immunoglobulin. Four polypeptide chains consisting of two 
identical light chains and two identical heavy chains linked by disulfide bonds form the Ig 
monomeric unit. Each chain has a variable region that forms the antigen binding sites, and 
each heavy chain contains a constant region that determines the function of Ig. 
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2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) 
 Dioxins refer to a group of toxic chemicals that consist of halogenated aromatic 
hydrocarbons (HAH). They have similarities in structure, properties, and mechanisms. 
HAH includes polychlorinated biphenyls (PCB), polychlorinated dibenzofurans (PCDF), 
and polychlorinated dibenzodioxins (PCDD). Dioxins have a long half-life and 
hydrophobic properties make them resistance to metabolism. This tend to bio-accumulate 
of dioxins in adipose tissues, especially with long-term exposure, and persist as 
environmental contaminants (Mandal 2005; Van den Berg et al., 1998).  
 The most studied PCDD is the potent and highly toxic dioxin 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). It is a planner molecule (C12H4Cl4O2) and insoluble 
in water (Fig. 2). In addition, it has no odor or color at room temperature and it is not 
intentionally produced by industry except in a limited quantity for research purposes. 
TCDD is produced from many industrial processes that have incomplete combustion of 
organic materials in presence of chlorine such as plastic production, herbicides and 
pesticides. Also it is produced from improper disposal of medical waste, metal smelting, 
diesel trucks, burning treated wood and forest fires (Malisch & Kotz, 2014; Strucinski et 
al., 2011). Biological effects of TCDD are dependent upon many factors including 
exposure duration and dose as well as species. In fact, exposure to TCDD could be through 
ingestion of contaminated food or water, inhalation of contaminated dust or cigarette 
smoke, and direct contact with incorporated soil or surfaces (Mandal, 2005).  
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 Figure 2. Chemical structure of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD). 
 
 During the Vietnam War (1961-1971), TCDD was discovered to be a contaminant 
in the herbicide Agent Orange when American military forces sprayed it on foliage to 
expose Vietnamese soldiers (Karch, et al., 2004). Additionally, in Seveso, Italy (1976), 
thousands of inhabitants were exposed to TCDD after an accidental explosion of a pressure 
tank containing substances contaminated with TCDD leading to the highest residential 
exposure to TCDD (Mandal 2005). Another incident happened in Vienna 1997 when two 
women were poisoned at their workplace with the highest measured dose of TCDD in 
human (144 ng/g of fat) (Geusau et al., 2001). The second highest exposure happened in 
Ukraine during the 2004 election campaign when Viktor Yushchenko was poisoned with 
TCDD (108 ng/g of fat) after a failed assassination attempt (Sorg et al. 2009). Humans 
seem to be less sensitive to toxic effects by TCDD than many laboratory animals (Poland 
& Knutson, 1982). In animal studies, exposure to TCDD caused immune dysfunction, 
endocrine disruption, teratogenesis, hepatic damage and tumorigenesis (Mandal 2005). 
11 
 
TCDD is not acutely life-threatening in humans but has been shown to induce death in 
sensitive animal species. For example, the lethal dose 50% (LD50) for TCDD varies from 
1 μg/kg for guinea pig, the most sensitive animal species, to >5000 μg/kg for hamster, the 
most resistant (Poland & Knutson, 1982). The main effects of TCDD on human in short-
term include blurred vision, nausea and development of severe chloracne. Whereas the 
long-term effects include vascular ocular changes, signs of neural system damage and 
immunological effects include effects on B cell lead to low level of immunoglobulin IgG 
in the circulation (Silbergeld & Gasiewicz, 1989; Dertinger et al., 2001; Marinkovic et al., 
2010). Additionally, TCDD has been classified as a human carcinogen because it promotes 
cancer development (IARC, 1997). The mechanism of TCDD toxicity in human is not clear 
yet, but the biological effects are thought to be mediated by the aryl hydrocarbon receptor 
(AhR) signaling pathway. 
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The Aryl Hydrocarbon Receptor (AhR) Signaling Pathway 
 The aryl hydrocarbon receptor (AhR) is a cytosolic receptor protein. It is a ligand-
activated transcription factor that is encoded by the Ahr gene and consists of 848 amino 
acids. The structure of AhR comprises of a basic-helix-loop-helix domain followed by Per-
ARNT-Sim protein domain (PAS). Therefore, it is part of the bHLH/PAS family of 
transcription factors (Gu et al., 2000). In mouse, the high concentrations of AhR have been 
found in most tissues especially thymus, liver and kidney, while in humans, it can be found 
in the placenta, lung, and liver, and low concentrations in brain, muscle and kidney 
(Carlstedt-Duke, 1979; Carver et al., 1994a; Dolwick et al., 1993; Yamamoto et al., 2004). 
The AhR is activated through binding to a variety of endogenous or exogenous ligands. A 
number of endogenous compounds such as indoles, 7-ketocholesterol, bilirubin and 
tetrapyroles have been identified as AhR ligands (Denison & Nagy, 2003). The majority 
of high-affinity AhR ligands are exogenous ligands like polycyclic aromatic hydrocarbons 
(PAHs) and halogenated aromatic hydrocarbons (HAHs). The ligand with the highest AhR 
binding affinity is 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Fig. 2). It is part of the 
HAH family and the prototypical ligand used in AhR studies (Abel and Haarmann-
Steeman, 2010). 
  In the absent of a ligand, AhR is an inactive protein located in the cytosol and bound 
to protective proteins to stabilize the whole complex. This complex consists of a dimer of 
heat-shock proteins (Hsp90) that protects from cell temperature elevation; co-chaperone 
p23, which prevents non-specific binding to ARNT; and XAP2, which binds to AhR and 
Hsp90 (Whitlock, 1999). Once ligand (e.g. TCDD) binds to the AhR in the cytoplasm, the 
AhR protein goes through a conformational change leading to its dissociation from the 
13 
 
complex of protective cytosolic proteins (Fig. 3). Then the TCDD-AhR complex 
translocates from the cytoplasm into the nucleus where it binds to the aryl hydrocarbon 
receptor nuclear translocator (ARNT) to form a heterodimer. The TCDD-AhR-ARNT 
heterodimer complex binds to specific DNA sequences (5’-TNGCGTG-3’) called dioxin 
responsive elements (DRE). Since DREs are located within the promoter or enhancer 
regions of target genes, the heterodimer complex causes upregulation or downregulation 
of gene expression (Abel & Haarmann-Stemmann, 2010) (Fig. 3). If the AhR ligand, which 
activates AhR signaling, is no longer present, the activation of the AhR can be controlled 
by either of two regulatory pathways; negative feedback inhibition mediated by the AhR 
transcriptional repressor (AHRR) or  cytosolic export of the AhR and degradation by 
ubiquitination and proteasome pathways (Abel & Haarmann-Stemmann, 2010). 
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Figure 3. Aryl hydrocarbon receptor signaling pathway.  TCDD binds to the AhR and 
cytoplasmic proteins dissociate.  TCDD-AhR translocates to the nucleus and binds ARNT.  
The complex of TCDD-AhR-ARNT binds to DRE sequences and modulates transcription. 
CYP1A1 is a sensitive indicator of AhR activation. 
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 The AhR has an important role in the regulation of xenobiotic metabolizing 
enzymes and drug metabolizing enzymes such as cytochrome P450A1 (CYP1A1) (Fig. 3). 
CYP1A1 is highly induced by TCDD, and it is one of the most characterized genes 
regulated by the AhR. It has been used as a biomarker for AhR activation (Hansen et al., 
2014; Whitlock, 1999). In addition to drug metabolism, the AhR signaling pathway is 
involved in crosstalk pathways with steroid receptors of androgen, estrogen and 
progesterone hormones by co-regulating gene transcription and expression (Ohtake et al., 
2008). Moreover, the AhR plays an important role in proliferation, differentiation, 
apoptosis and survival of cells. Also, it has effects in the immune system, it mediates 
immunological responses by inhibiting inflammation through induction of interleukin-22 
(IL-22) and down-regulation of Th17 and CD4+ T cell response (Monteleone et al., 2011; 
Wei et al., 2014), and the AhR has main role in inhibition of Ig production through 
suppression of B-cell proliferation and differentiation  (Sulentic & Kaminski, 2011). 
 Mouse AhR studies show that the AhR is highly responsive to TCDD and the 
mouse AhR has ten-fold higher affinity compared to the human AhR (Denison et al., 1986). 
In addition, the human and mouse AhR gene have single nucleotide polymorphisms (SNPs) 
in different locations and they only share about 58% amino acid sequence identity in the 
C-terminal of the gene, which includes the transactivation domain (Flaveny et al. 2008). 
The SNPs in exon 10 of the human AhR have been reported in association with decreased 
CYP1A1 induction by AhR in response to TCDD (Wong, et al., 2001). The lower affinity 
of the human AhR and the exon 10 SNPs may explain why animal models are more 
sensitive to TCDD than human. Interestingly, the exon 10 SNPs did not affect the ligand 
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binding affinity, also the SNPs located in the ligand-binding domain did not affect the 
ligand-induced CYP1A1 expression (Harper et al., 2002). 
The Aryl Hydrocarbon Receptor Antagonist (AhRA) 
 In animal models, the AhR plays an important role in mediating toxicity and 
inducing activity of the TCDD; therefore inactivation of the AhR signaling pathway would 
be estimated to offer protection from TCDD toxicity. High affinity ligands for the AhR 
include toxic compounds such as halogenated aromatic hydrocarbons HAHs, polycyclic 
aromatic hydrocarbons PAHs and PAH-like compounds (Denison et al., 1998). Other 
natural and endogenous AhR ligands have been identified but they have different chemical 
structures and characteristics from HAH and PAH AhR ligands, which suggests that the 
ligand-binding pocket of the AhR is very promiscuous (Denison et al., 1998). Since 
structurally diverse ligands can bind to different amino acids within the ligand-binding 
pocket of the AhR, it could be possible to determine an antagonist that could affect one or 
a group of ligands over another (Zhao et al. 2010). Some of the AhR antagonists lack of 
specificity due to two reasons; they have binding affinity to the estrogen receptor that 
enhance the estrogen-related effects or they are partial agonists such as flavones that at 
high doses act as AhR agonists (Zhang et al., 2003; Amakura et al. 2002). The CH223191 
compound has been identified as a pure AhR antagonist, which competes and inhibits 
binding of TCDD to the AhR, and prevents the AhR from translocating to the nucleus and 
binding the DNA (Fig. 4) (Kim et al. 2006). It is a selective AhR antagonist for HAH 
compounds while no antagonism effect on AhR activated by different concentration of 
PAH or non-PAH AhR agonists (Zhao et al. 2010). In addition, it does not show AhR 
agonist-like activity at high doses or any binding affinity to the estrogen receptor, therefore 
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CH223191 (AhRA) is the best candidate compound to elucidate the role of the AhR when 
it is activated by TCDD (Zhao et al. 2010). This compound has been tested in our lab with 
the mouse B-cell line (CH12.LX) and it inhibits the AhR signaling pathway and decreases 
the expression of CYP1A1 in response to TCDD (Wourms & Sulentic, 2015). In another 
study on the CL-01 human B-cell line, the AhRA and TCDD demonstrated inconstant 
effects on IgM secretion but they antagonized each other’s effect on IgG secretion. 
Surprisingly, activated CL-01 cells by the AhRA induced IgG secretion by two-fold (Burra, 
2015 data not published). 
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Figure 4. AhR antagonist (AhRA) inhibits translocation of AhR into the nucleus. 
AhRA competes and blocks TCDD binding to the AhR as well as TCDD-mediated nuclear 
translocation and DNA binding activity of the AhR. 
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The Immunological effects of TCDD 
 The immune system is an early and sensitive target to TCDD-induced toxicity. A 
wide range of TCDD concentrations can cause significant immunological dysfunction 
including suppression of both innate and adaptive immunity and inhibition of cell-mediated 
and humoral immunity (Mandal, 2005; Abel & Haarmann-Stemmann, 2010). In animal 
studies, acute or chronic exposure to TCDD causes thymic atrophy, endocrine disruption, 
hepatic damage and immunological effects include immune-cell dysfunction and 
suppression of immune responses that lead to susceptibility to infectious diseases 
(Kerkvliet, 2002; Mandal, 2005; Safe, 1998). TCDD improved the induction of Treg cells, 
which suppressed T-cell proliferation (Quintana et al. 2008), and TCDD inhibited Ig 
production through suppression of B-cell differentiation (Sulentic & Kaminski, 2011). As 
mentioned the effects of TCDD on humans are less sensitive than animals (Denison et al., 
1986). In human, several epidemiological studies found that an association between people 
exposed to TCDD and non-Hodgkin’s lymphoma or multiple myeloma (Becher et al., 
1996; Hooiveld et al., 1998). Among people living in highly TCDD contaminated area, 
there was 2.3 times greater incidence of non-Hodgkin’s lymphoma than people living in 
low TCDD contamination (Floret et al., 2003). Another study found that prenatal exposure 
to TCDD affects humoral immune status of their children after birth through demonstrated 
of reduced vaccine titers and increased incidence of otitis and chicken pox (ten Tusscher 
et al., 2003). Moreover, exposure to TCDD for a long time mediates B-cell immunotoxicity 
such as markedly decreased the IgG levels in circulation (Baccarelli et al., 2002). TCDD 
also increased the production of only IgE isotypes from B cells isolated from atopic patients 
(Kimata, 2003). 
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TCDD-Induced B-cell Dysfunction 
 B cells are an essential component of the humoral immune response and are a 
sensitive direct target of TCDD. In mouse models, TCDD affects B-cell maturation and 
gene regulation that lead to suppression of immunoglobulin production (Lu et al. 2010; 
Sulentic and Kaminski 2011). TCDD inhibits B-cells differentiation into antibody-forming 
cells mediated by the AhR (Wourms & Sulentic, 2015; Vorderstrasse et al., 2001). TCDD 
inhibits B-cell differentiation induced with T-helper function (T-dependent) by activating 
B-cell with sheep red blood cells or without T-helper function (T-independent) using 
lipopolysaccharide (LPS) for activating B-cell (Holsapple et al., 1986). In a mouse B-cell 
line (CH12.LX) stimulated with LPS, TCDD in a concentration-dependent manner (0.03-
30nM TCDD) decreased IgM secretion, whereas it did not affect IgM secretion in an AhR-
deficient B-cell line (BCL-1) stimulated with LPS, suggesting that AhR plays an important 
role in inhibition of IgM secretion by TCDD (Sulentic et al., 1998). Moreover, in an IgA 
secreting B-cell line that has the AhR knocked down by shRNA or the AhR inhibited by 
an AhR antagonist prevented TCDD-induced inhibition of IgA secretion (Wourms & 
Sulentic, 2015). Another study with AhR-/- mice showed normal immune function and Ig 
production after treatment with TCDD (Vorderstrasse et al., 2001). These studies support 
an important role of the AhR in TCDD-induced inhibition of Ig and B-cell differentiation 
and inactivation of the AhR has no effect in normal immune function (Wourms & Sulentic, 
2015; Vorderstrasse et al., 2001).  
 Human B-cells appear to have a variable response to TCDD. In human primary B-
cells, TCDD suppressed IgM in nine donors while having no effect in two donors and 
increased IgM in one donor (Lu et al., 2010). In addition, it suppressed the differentiation 
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of human primary B cells by inhibiting the activation markers CD69, CD86 and CD80 (Lu 
et al. 2011).  In a study of people who live in TCDD-contaminated areas including residents 
in Seveso, Italy and Korean veterans, decreased plasma IgG levels were reported 
(Baccarelli et al., 2002 ; Kim et al., 2003). In another study on human B cells, TCDD had 
variable effects on IgM secretion and µ IGH functional transcripts while IgG secretion and 
γ1-4 germline/functional transcripts were inhibited (Burra 2015, unpublished data). Whereas 
in tonsillar mature B cells, TCDD induced IgE production without affecting production of 
other Ig isotypes (IgG, IgM or IgA) in patients with allergic rhinitis, atopic 
eczema/dermatitis syndrome, or bronchial asthma with no effects on Ig isotypes in other 
patients, suggesting that allergic diseases could be aggravated by TCDD (Kimata, 2003). 
Additionally, the Ig heavy chain regulatory region (3’IghRR) mediates TCDD-induced 
suppression of B-cell differentiation in mouse models but its role in humans is unknown 
(Wourms & Sulentic, 2015; Fernando et al., 2012; Sulentic et al., 1998). Overall, the 
mechanism of TCDD and AhR in mediating B-cell dysregulation by TCDD in mouse is 
relatively well defined whereas the mechanism in humans is still unclear. 
Immunoglobulin Heavy Chain (IgH) Locus 
 The human Ig heavy chain (IGH) gene is located on chromosome 14 and the mouse 
Ig heavy chain (Igh) gene is located on chromosome 12. They encode the heavy chain of 
antibodies during early B-cell development and differentiation by DNA remodeling events 
such as VDJ recombination, class switch recombination (CSR), and somatic hypermutation 
(SHM) (Pinaud et al. 2011). The rearranged Ig heavy chain (IGH) gene consists of variable 
heavy chain promotor (VH), variable region (VDJ), the heavy chain intronic enhancer (Eµ), 
the heavy chain constant region genes (CH), and the 3’ immunoglobulin heavy chain 
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regulatory region (3’IgHRR) (Fig. 5) (Mills et al. 1997). The VH promoter initiates and 
regulates the transcription of the IGH locus and gene expression, while the VDJ gene 
encodes the antigen binding sites. The intronic enhancer (Eµ) is important for efficient VDJ 
recombination and Cµ expression (Perlot et al. 2005). In Burkitt’s lymphoma, translocation 
of the 3’IGHRR with the cellular oncogene MYC deregulates gene expression (Yan et al., 
2007). In addition, the chromosomal translocation between BCL-2 gene and 3’IGHRR in 
follicular lymphomas deregulates gene expression and increases cell death resistance 
(Heckman et al., 2003). Other studies showed that Igh transcription in a mutant myeloma 
cell line was significantly inhibited after deletion in a sequence downstream of Cα leading 
to the discovery of the 3’IghRR (Gregor & Morrison, 1986). The mouse and human heavy 
chain locus are 90% homologous but there are some differences (Mills et al. 1997).  The 
human IGH has two groups of constant regions with two 3’IGHRRs each has three 
enhancers (hs3, hs1.2, hs4) while the mouse Igh has one group of constant region with one 
3’IghRR that has four enhancers (hs3a, hs1.2, hs3b, hs4) (Fig. 5). In human IGH, upstream 
of each 3’IGHRR are constant region genes that encoding for specific heavy chain isotypes. 
The first set of heavy chain constant region (CH) genes include Cμ, Cδ, Cγ3, Cγ1, Cψε and 
Cα1, followed by the first regulatory region 3’IGHRR-1. The second set of constant region 
genes located downstream of 3’IGHRR-1 that include Cγ2, Cγ4, Cε and Cα2, followed by 
the second regulatory region 3’IGHRR-2 (Mills et al. 1997). The mouse Igh has one set of 
CH genes that include Cμ, Cδ, Cγ3, Cγ1, Cγ2b, Cγ2a, Cε and Cα followed by one regulatory 
region 3’IghRR (Fig. 5) (Madisen and Groudine 1994). 
 
 
23 
 
 
 
 
 
Figure 5. Human and mouse immunoglobulin heavy chain (Iɡh) gene locus. VH, 
variable heavy chain promoter; Eμ, intronic enhancer;  long rectangles, IgH constant region 
genes; short rectangles, germline promoters; 3’IghRR, regulatory region; hs, 
hypersensitivity site. 
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The mouse 3’ Immunoglobulin Heavy Chain Regulatory Region (3’IghRR) 
 The mouse Igh locus has one 3’IghRR and this region is about a 40 kb DNA 
segment. The main role of the 3’IghRR is to control and regulate the transcription of the 
Igh gene and class switch recombination (CSR), but it does not appear to play a role in 
VDJ recombination (Cogne et al., 1994; Ju, Chatterjee, & Birshtein, 2011). It has four 
major DNAase I hypersensitive elements (hs3a, hs1.2, hs3b, and hs4), which are regions 
of chromatin that are sensitive to cleavage by the DNase I enzyme (Fig. 5). The hs1.2 
enhancer has transcriptional activity in a mature B cell and plasma cell, the hs3a and hs3b 
enhancers have minor activity in B cells or plasma cells, while the hs4 has transcriptional 
activity throughout B-cell development especially pre-B cell and plasma cells. 
Replacement of mouse hs1.2 enhancer with neomycin resistance gene resulted in decreased 
CSR into IgG2a, IgG2b, IgG3 and IgE (Cogne 1994). On the other hand, the four enhancers 
display maximum activity at all stages of B-cell development when all four enhancers are 
link together (Matthias and Baltimore, 1993; Madisen and Groudine, 1994; Chauveau et 
al., 1998; Saleque et al., 1997). They have several binding sites for transcription factors 
including DRE, NF-κB, Octamer (OCT), NF-αP, AP-1/Ets, and Pax5 that regulate 
3’IghRR activity (Fig. 6). Therefore the mouse 3’IghRR could be a sensitive target of 
several exogenous and endogenous toxic chemicals such as the AhR-ligand TCDD. 
 Past research shows that transcriptional activity of mouse 3’IghRR in CH12.LX 
cells stimulated with LPS is inhibited by TCDD (Sulentic et al., 2004a). This effect matches 
the suppression of Cµ gene expression and IgM secretion by TCDD (Sulentic et al., 2000). 
The mouse 3'IghRR has a DRE motif in the most transcriptional active enhancers hs1.2 
and hs4, and TCDD was shown to induce binding of AhR/ARNT to DRE sites within these 
25 
 
enhancers (Salisbury & Sulentic, 2015; Sulentic et al., 2000). Suggesting that mouse 
3’IghRR is a transcriptional target of the AhR signaling pathway, and because this region 
is important for CSR and Igh transcription, it could mediate the TCDD-inhibitory effect on 
the Ig expression (Sulentic et al., 2004a). However, 3’IghRR enhancers react differently 
with TCDD when evaluated in isolation. When the CH12.LX cell line was transfected with 
a plasmid reporter regulated by either the hs4 or the hs1.2 enhancer, the transcriptional 
activity of the hs4 enhancer was increased, while the hs1.2 enhancer was suppressed by 
TCDD (Sulentic et al., 2004b; Fernando et al., 2012). Moreover, the deletion of the hs4 
enhancer does not affect class switch recombination (CSR) or Ig production in mouse cells 
stimulated with LPS or cytokines (Vincent-Fabert et al., 2009). These outcomes are against 
the effect of TCDD on the full length 3’IghRR suggesting that the hs4 enhancer has an 
unrelated or different role with TCDD while inhibition of the hs1.2 enhancer by TCDD 
may be responsible for the inhibitory effect on 3’IghRR transcriptional activity. 
Interestingly, the mouse hs1.2 enhancer has two binding sites for paired box protein (Pax5) 
but the human hs1.2 enhancer does not have any Pax5 binding sites (Fig. 6) (Schneider et 
al., 2009). The Pax5 transcription factor plays a main role in early stages of B-cell 
development and must be downregulated to allow for differentiation of B cells into plasma 
cells (Cobaleda et al., 2007). Pax5 levels are decreased in LPS-stimulated mouse B-cell, 
but TCDD co-treatment inhibits this down-regulation (Yoo et al., 2004; Schneider et al., 
2008). Deregulation of Pax5 expression after TCDD treatment implies that Pax5 plays a 
role in TCDD-mediated inhibition of Ig expression and B-cell differentiation (Schneider et 
al., 2009). 
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The Human Immunoglobulin Heavy Chain Regulatory Region (3’IGHRR) 
 The human IGH locus has two regulatory regions: 3’IGHRR-1 located downstream 
of Cα1 and the 3’IGHRR-2 located downstream of Cα2. Each regulatory region is 
composed of three DNAase I hypersensitive elements (hs3, hs1.2 and hs4) (Fig. 5) 
(Chauveau & Cogne, 1996; Mills et al., 1997). The duplication of the 3’IGHRR in the 
human locus is thought to be functionally significant, but no studies have investigated the 
specific roles of the two 3’IGHRRs in antibody expression. The three human enhancers,  
hs3, hs1.2 and hs4, share 74%, 90% and 76% similarity, respectively to the mouse 
enhancers. TCDD treatment was expected to result in reduced activity of the 3’IGHRR 
since TCDD is known to act as an immunosuppressant in both mouse and human B cells. 
In luciferase reporter studies, when the human 3’IGHRR plasmids with different promotors 
(i.e. VH, Iγ3 and Iε) were transfected into B cells and treated with TCDD, they exhibited 
highly variable and statistically insignificant change in activity (Alfaheeda 2016, 
unpublished data). In addition, several lymphomas, which are B-cell malignancies, have 
chromosomal translocation between oncogenes like C-MYC or BCL-2 and the heavy chain 
regulatory region 3’IGHRR that lead to cancer such as Burkitt’s lymphoma or multiple 
myeloma (Heckman et al., 2003).  
 Among the three human enhancers, the human hs1.2 enhancer is the most important 
one and it plays a main function in the control of transcription (Guglielmi et al., 2004; 
Cogne et al., 1994). Unlike the mouse hs1.2, the human hs1.2 enhancer actually decreases 
activity in response to human B-cell stimulation and increases activity in response to 
TCDD in both a mouse (CH12.LX) and human (IM-9) B-cell line, which is exactly the 
opposite of the stimulatory effect of cellular activation on the mouse hs1.2 and inhibition 
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by TCDD  (Fernando et al., 2012). Additionally, the activity of the human hs4 enhancer 
alone is slightly reduced by TCDD unlike the stimulatory effect of TCDD on mouse hs4 
activation (Alfaheeda 2016, unpublished data). These conflicting results between hs1.2 and 
hs4 enhancers could partially explain why 3’IGHRR plasmid did not respond to TCDD at 
all. The AhR antagonist was used to confirm that TCDD-induced activation of human hs1.2 
enhancer requires the AhR (Fernando et al. 2012). Other studies have shown that the AhR 
can bind to other transcription factors like SP1, NF-κB and AP-1 (Suh et al., 2002; Tian et 
al., 1999; Kobayashi et al., 1996) therefore, the AhR could be directly or indirectly 
involved in the hs1.2 activation by TCDD. 
 The hs1.2 enhancer in mouse and human are almost the same and similar in about 
90% of the DNA sequences, but there are many important differences between them that 
could explain the different effects by TCDD (Mills et al., 1997). The human hs1.2 enhancer 
has a polymorphic region consisting of a 55 bp repeated sequence called the invariant 
sequence (IS), which can be repeated up to four times, and appears to alter transcriptional 
activity (Fig. 6). This polymorphism does not occur in the mouse hs1.2 enhancer (Denizot 
et al., 2001) so all studies involving the mouse Igh locus have missed any functional 
significance of the human polymorphism. Moreover, the IS has binding sites for several 
transcription factors including NF-κB, NF-1, AP-1 and the AhR (Fig. 6). Unlike the mouse 
enhancers, the human enhancers have NF-1 binding sites but they do not have binding sites 
for Pax5 transcription factor, which is a negative regulator of B-cell differentiation into 
antibody-secreting cells (Fernando et al. 2012; Chen and Birshtein 1997; Denizot et al. 
2001). The transcription factors binding sites are increased with each additional IS, which 
is correlated with an increase in the basal transcriptional activity of the hs1.2 enhancer 
28 
 
(Cogné et al., 1994). The NF-1 binding site could mediate the TCDD-induced activation 
of human hs1.2 enhancer since the mutation of the NF-1 binding site has a lower sensitivity 
to TCDD (Snyder 2016, unpublished data). In contrast, another study found that mutation 
of the AP-1 and NF-κB site increased the human hs1.2 enhancer activity by TCDD 
suggesting that these sites have repressor roles (Ochs 2012, unpublished data). The 
polymorphic region in the human hs1.2 enhancer makes the human heavy chain locus more 
complex than the mouse locus. This polymorphism has drawn particular interest, because 
it has been associated with Burkitt’s lymphoma and a number of autoimmune disorders 
such as celiac disease, psoriatic arthritis, IgA nephropathy, rheumatoid arthritis, systemic 
sclerosis, and plaque psoriasis. The hs1.2 allele 2, which has two IS repeats, has been 
correlated with enhanced prevalence or severity of the previous disorders (Tolusso et al., 
2009; Giambra et al., 2009; Cianci et al., 2008; Aupetit et al., 2000; Frezza et al., 2004). 
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Figure 6. Differences between mouse and human hs1.2 enhancers. The hs1.2 enhancer 
is densely packed with transcription factor binding sites. A 55 base pair invariant sequence 
(IS) in human hs1.2 enhancer is polymorphic and can be repeated up to four times. AP-1 
activator protein 1; Oct, octamer; Sp1, specificity protein 1; NF-κB, nuclear factor kappa 
B cells; DRE, dioxin responsive element; NF-1, nuclear factor 1; Pax5, paired box 5. 
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AhR interacts with cytosolic signaling proteins. 
 In the absent of a ligand, AhR is an inactive protein located in the cytosol and bound 
to protective proteins complex. Once ligand binds to the AhR in the cytoplasm, the AhR 
protein goes through a conformational change leading to its dissociation from the complex 
of protective cytosolic proteins (Abel & Haarmann-Stemmann, 2010). An additional 
mechanism for the AhR activity is through protein-protein interactions with regulatory 
proteins such as Src protein kinase and NFκB after dissociation from the proteins complex 
in the cytosol (Enan and Matsumura, 1996; Tian et al., 1999). Moreover, the AhR signaling 
pathway has been shown to modulate a number of signaling pathways such as tyrosine 
kinases associated with the epidermal growth factor receptor (EGFR) and Akt/PKB 
(Marlowe & Puga, 2005). Therefore, the biological effects of the AhR could occur via at 
least two general mechanisms: direct influence on gene transcription by binding to DRE 
motifs and/or modulate signaling pathways by protein–protein interaction (Suh et al., 
2002). 
 Src family kinases are cytoplasmic proteins that are associated with the plasma 
membrane via lipid anchors at their N termini. The Src tyrosine kinase is overexpressed 
and activated in B-cell malignancies and dysregulation of Src activity is thought to be the 
key contributor to oncogenesis (Ye et al., 2016). Src family kinases (Lyn, Fyn, Fgr, Blk) 
play a role in initial phosphorylation of cytoplasmic immunoreceptor tyrosine-based 
activation motif (ITAM) of the Igα and Igβ that activate Syk, which is the dominant 
tyrosine kinase activity in B cells, leading to B-cell activation (Xu et al.,2012). Indeed, Src 
deficient mice displayed a profound block in B-cell development (Stepanek et al., 2013). 
Moreover, Park et al. (2007) indicated that TCDD-induced activation of Src kinase is 
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mediated by the cross-talk between the ligand-activated AhR in the cytosol and the 
cytosolic Src chaperone complex (Src-cdc37-Hsp90 complex). In another study, Src 
protein kinase is associated specifically with the cytosolic AhR complex along with hsp90 
and upon ligand binding to the AhR, Src is activated and released from the complex (Enan 
& Matsumura, 1996).    
 Consistent with Src kinase, the phosphoinositide 3-kinase (PI3K)/protein kinase B 
(Akt) pathway plays a crucial role in multiple cellular processes, including cell 
proliferation, angiogenesis, metabolism, differentiation and survival. The members of the 
PI3K/Akt pathway are dysregulated in a wide spectrum of human B-cell cancers. Akt 
signaling triggers a cascade of responses, from cell growth and proliferation to survival 
and motility, which drive tumor progression (Vivanco, & Sawyers, 2002). Phosphorylated 
Akt activates the mTOR complex, causing increased mRNA translation, protein synthesis 
and cellular proliferation (Agata et al., 2010). Akt/forkhead box O (FoxO) pathway is a 
major pathway involved in B-cell differentiation and function. Activation of BCR by 
antigen leads to the transformation phosphatidylinositol bisphosphate (PIP2) to 
phosphatidylinositol triphosphate (PIP3) that phosphorylates Akt. The p-Akt enters the 
nucleus to inactivate FOXO protein, which blocks cell cycle progression and promotes 
stress resistance, that help in B-cell prolifration (Limon & Fruman, 2012). Basal expression 
of p-Akt was observed in the CA46 Burkitt lymphoma cell line under untreated conditions 
(Huang et al., 2012). Many studies have shown that AhR regulates Akt activation. Lack of 
the AhR leads to impaired activation of Akt and enhanced sensitivity to apoptosis in a 
hepatoma cell line (LA1) (Wu et al., 2007). Another study showed that the AhR signaling 
pathway controls breast cancer cell proliferation and development through inhibition of the 
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phosphatase and tensin homolog (PTEN) and activation of β-Catenin and Akt pathways 
(Al-Dhfyan et al., 2017).  
 The nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) protein 
is sequestered in the cytoplasm and their activity is regulated by binding of inhibitory κB 
factors (IκB). Upon activation, NFκB dimers dissociate from IκB and translocate to the 
nucleus then bind to the NFκB binding sites (κB site) in promoters and enhancers of NFκB 
responsive genes, consequently activating their transcription (Doi et al., 1997). The 
NFκB/Rel plays a main role in regulation of B-cell activation and diffrentiation 
(Gerondakis & Siebenlist, 2009). RelA/p50 is the major NFκB in pre-B cells and plays an 
important role in certain steps of B-cell development (Liou et al., 1994). RelA-deficient 
mouse B cells have the ability to secrete all immunoglobulins except IgG1 and IgA were 
reduced (Doi et al., 1997). The AhR and NFκB pathways interact by physical association 
of Re1A and AhR, and this interaction is associated with modulation of gene expression 
(Tian et al., 1999). The κB binding site is close proximity to the DRE binding site within 
the hs1.2 enhancer while it overlaps the DRE site within the hs4 enhancer (Sulentic et al., 
2000). Binding of both the AhR and NFκB cooperatively influenced hs4 reporter activity 
(Sulentic et al., 2004b). Moreover, another study suggested that interaction between the 
AhR and NFκB proteins mediates the inhibitory effects of TCDD on 3’IghRR and Ig 
expression (Salisbury & Sulentic, 2015). 
 AP-1 is another transcription factor binding site in the hs1.2 enhancer of the 
3’IGHRR (Pinaud et al., 2011). B-cell signaling initiated at TLRs activates Jun N-terminal 
kinase (JNK). JNK phosphorylates c-Jun and c-Fos, which are components of AP-1, 
increasing the AP-1 transcription activity that lead to plasmacytic differentiation and Ig 
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production (North et al., 2010). AP-1 forms a transcriptional complex with ETS in 
activated B cells that bind to an ETS/AP-1 motif in the mouse 3’IghRR enhancers that 
plays a main role in class switch recombination (Grant et al., 1995). It has a main role in 
the regulation of B-cell activation and differentiation since the surface IgM cross-linking 
or activation of CD40 induced the expression of AP-1 (Chan et al., 1993). In addition, AP-
1 is involved in Ig production by transactivation of the promoter for κ light chain (Schanke 
et al., 1994). Another study showed that inhibition of AP-1 activity by TCDD is AhR-
dependent and partially contributes to TCDD-mediated suppression of IgM expression in 
mouse B cells (Suh et al., 2002). 
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Hypothesis and Objectives: 
 In a mouse B-cell line, TCDD suppresses B-cell differentiation and inhibits IgM 
secretion (Sulentic & Kaminski, 2011). This suppression is mediated by the AhR pathway 
(Wourms & Sulentic, 2015; Vorderstrasse et al., 2001) perhaps by the AhR binding DRE 
sites within the hs1.2 enhancer of the mouse 3’IghRR (Sulentic et al., 2000; Salisbury & 
Sulentic, 2015). Moreover, the AhRA (CH223191) inhibits the AhR signaling pathway and 
decreases the inhibition of Ig production in response to TCDD (Wourms & Sulentic, 2015; 
Salisbury & Sulentic, 2015). In a human B-cell line, IgG secretion is inhibited in response 
to TCDD but antagonism of the AhR [CH223191 or 6,2’,4’,-trimethoxyflavone (TMF)] 
increased IgG secretion about two-fold (Burra 2015; Panstingel 2017, unpublished data). 
In addition, AhR knockdown by shRNA showed that IgG secretion was nearly eliminated 
(Kashgari 2015, unpublished data). Other studies have shown that the AhR can interact 
directly or indirectly with different transcription factors like SP1, NF-κB and AP-1 
(Kobayashi et al., 1996; Suh et al., 2002; Tian et al., 1999). The AhR signaling pathway 
has also been shown to modulate a number of signaling pathways such as Src and Akt/PKB 
(Marlowe & Puga, 2005). These data suggested that the AhR antagonist could cause a 
conformational change in the cytosolic AhR resulting in activation of other cytoplasmic 
proteins that leads to an increase in IgG secretion. In addition, the human AhR has SNPs 
that decrease CYP1A1 induction by TCDD (Flaveny et al. 2008; Wong, et al., 2001). In 
CL-01 human B cells, AhR is heterozygous with a non-functional transactivation domain 
in one of its alleles due to three SNPs in exon-10 (Kashgari 2015, unpublished data). These 
SNPs could explain why TCDD has variable effects on human 3’IGHRR reporters in the 
CL-01 cells (Alfaheeda 2016, unpublished data). Moreover, knockout of the AhR will help 
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to elucidate the role of the AhR in Ig expression and 3’IGHRR activity in response to 
TCDD or AhR antagonism. Therefore, we hypothesized that in human cells the AhR 
regulates IGH expression by altering 3’IGHRR activation through both genomic and non-
genomic mediated mechanisms. To test this hypothesis, three main experimental objectives 
were developed utilizing the human CL-01 B-cell line. Objective one was to evaluate the 
potential non-genomic effects of the AhR on the activation of cytosolic signaling proteins 
(i.e. phosphorylation and activation of downstream transcription factors). Objective two 
was to determine the role of the AhR transactivation domain in the regulation and activity 
of the 3’IGHRR enhancers by using CL-01 cells expressing an AhR with a functional 
transactivation domain. Objective three was to directly evaluate the role of the AhR in the 
effects of the AhRA and TCDD on Ig expression and 3’IGHRR activity using CRISPR/Cas 
9 gene editing to knockout the AhR. Significantly, the human 3’IGHRR has a 
polymorphism in the hs1.2 enhancer that has been associated with Burkitt’s lymphoma and 
a number of autoimmune disorders such as celiac disease, psoriatic arthritis, IgA 
nephropathy, rheumatoid arthritis, systemic sclerosis, and plaque psoriasis. Consequently, 
determining the role of the 3’IGHRR and its potential sensitivity to the AhR could provide 
a greater understanding of IGH regulation in general and new insight into potential 
environmental triggers of immune disorders, perhaps providing new targets for drug 
development. 
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II MATRIALS AND METHODS 
Chemical and Reagents 
 TCDD with 99.1% purity was purchased from AccuStandard, Inc and was 
dissolved in 100% DMSO. Dimethyl sulfoxide (DMSO) was purchased from Sigma-
Aldrich (St. Louis, MO). R848, a TLR 7/8 ligand, was dissolved in 100% DMSO and was 
purchased from Enzo Life Sciences. The AhR antagonist (CH223191) was purchased from 
Calbiochem (Carlsbad, CA) and was dissolved in 100% DMSO. Human interleukin 4 (hIL-
4) was purchased from Cell Signaling and dissolved in 1x phosphate buffer saline (PBS) 
with 10% bovine calf serum (BCS). Human Mega CD40 ligand (CD40L) was purchased 
from Enzo Life Sciences (San Diego, CA) and was reconstituted in 100 μl sterile H2O and 
further dilution in fresh media with 10% BCS. 
Cell Line Models 
 The Novus CL-01 human cell line was isolated from a Burkitt’s lymphoma patient. 
It is a human monoclonal B-cell line that expresses surface IgM and IgD. It was purchased 
from Novus Biologicals (Littleton, CO). Cells were cultured at 37°C in a 5% CO2 
atmosphere and grown in RPMI-1640 (Mediatech, Herndon, VA) enhanced with 2 mM L-
glutamine, 10% BCS (Hyclone, Logan, UT), 13.5 mM HEPES, 0.1 mM nonessential amino 
acids, 1.0 mM sodium pyruvate, 100 units/ml penicillin, 100 μg/ml streptomycin, 50 μM 
β-mercaptoethanol and 23.8 mM sodium bicarbonate. The medium was changed every 2-
3 days by simply removing some supernatant and adding some fresh medium. CL-01 cell 
line is EBV transformed and the cells can activate each other easily by cell-cell contact. 
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The cells were kept in density within the range between 0.1-0.2 x 106 cell/ml. they would 
be hyper-activated if too crowded, and die if too diluted. The cells were discarded after 4-
5 generations or after one month of thawing the cells unless requiring linger culture to do 
growing up a clone from a single cell.  
Reporter Plasmid Constructs 
 The plasmids were constructed using a pGL3 basic luciferase reporter backbone 
(Promega, Madison, WI) containing ampicillin resistance and the luciferase gene. The 
DNA sequence of the variable heavy chain (VH) (179 bp, AJ851868.3 from 562798 to 
562976, NCBI), gamma3 (Iγ3) (176 bp, NG_001019.6 from 1104579 to 1104754, NCBI) 
or epsilon (Iε) (291 bp, X56797.1 from 239 to 529, NCBI) promoters was inserted into the 
5’ multiple cloning site within the pGL3 luciferase reporter, and the human 3’IGHRR 
enhancers hs3, hs1.2, hs4 were inserted into 3’ of the luciferase gene in the pGL3 reporter 
plasmid containing one of the above promoters (Fig. 7). The plasmid constructs have the 
intervening sequences between hs3 and hs1.2 but lack the intervening sequences between 
hs1.2 and hs4 enhancers because this part is about 10 kb that makes it difficult to include 
it in plasmid construct. 
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Figure 7. Human 3’IGHRR reporter plasmid constructs with VH, Iγ3 or Iε promoters. 
Each plasmid contains a luciferase gene regulated by hs3, hs1.2, hs4 enhancers of the 
human 3’IGHRR. They include the intervening sequence between hs3 and hs1.2 enhancers 
and lack it between hs1.2 and hs4 enhancers. 
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 The DRE luciferase reporter has six DRE binding sequences inserted into a pGL3 
luciferase reporter with a SV40 promoter (Kress et al., 1998). NFκB luciferase reporter 
contains three consensus κB DNA binding sequences derived from the Ig κ light chain 
conjugated within the conalbumin promoter (Arenzana-Seisdedos et al., 1993). For the AP-
1 luciferase reporter plasmid, three AP-1 sequences (Vasanwala et al., 2002) were inserted 
into a pGL3 luciferase reporter with a SV40 promoter (Fig. 8). 
 
 
 
Figure 8. Luciferase reporters evaluating the activity of the transcription factors 
AhR, NFκB, and AP-1. 6x DRE plasmid contains six repeats of DRE motifs upstream of 
the SV40 promoter. 3x NFκB plasmid contains three repeats of κB sequence conjugated 
with Conalbumin (ConA) promoter. 3x AP-1 plasmid has three AP-1 binding motifs 
upstream of the SV40 promoter.  
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Transient Transfection 
 CL-01 cells (1x107) were pelleted by centrifugation at 500 x g for 5 minutes at 4°C. 
The pellet was re-constituted with 10 μg of plasmid and fresh complete media to a total 
volume of 200 µl then transferred to a 2mm electroporation cuvette. The cells were 
electroporated at 150 V, 1500 μF, and 75 ohms. Multiple transfections were performed for 
each plasmid and transfected cells were pooled together then diluted in culture tubes to 
obtain 1.5 x 105 cell/ml. Cells were cultured without any treatment [naïve (NA)], or treated 
with 0.01% DMSO [vehicle control (VH)] or 30 nM TCDD in absent or presence of cellular 
stimulation (1 µg/ml R848 or 6.25 ng/ml CD40L with 50 ng/ml IL-4). In AhR antagonist 
(AhRA) experiments, transfected cells in culture tubes were treated with 10 µM AhRA and 
incubated for 1 hour at 37oC prior to additional treatments. 2 ml of treated cells (1.5 x 105 
cell/ml) were aliquoted into a 12-well plate. The plates were incubated at 37oC in 5% CO2 
for 24 or 48 hours.  
 Following the incubation period, the cells were centrifuged for 5 min at 500 x g at 
4oC to collect the pellets. Supernatant was removed and cells were lysed with 1x reporter 
lysis buffer (Promega). Lysates were immediately frozen at -80oC. To measure the 
luciferase enzyme activity, samples were prepared by thawing on ice then centrifugation 
at 14,000 x g for 5 minutes at 4oC. In a glass tube, 20 µl of supernatant was mixed with 
100 µl of luciferase substrate reagent (Promega, Madison, WI), then luciferase activity, 
measured as relative light units (RLU), was determined using a luminometer (Berthold 
Detection Systems, Oak Ridge, TN). 
 
41 
 
Transfection Efficiency 
 When evaluating multiple plasmids or different clonal populations of the CL-01 
cells (i.e. AhR knockdown clones), the transfection efficiency was determined by 
measuring the amount of luciferase gene within the transfected cells by real-time 
polymerase chain reaction (RT-PCR) and normalizing the RLU to the transfection 
efficiency relative to either a control plasmid or the WT CL-01 cells. Briefly, DNA was 
isolated using a genomic DNA miniprep kit (Sigma) at 2-4 hours post-transfection. Real 
time polymerase chain reaction (RT-PCR) was performed on the extracted DNA using 
luciferase forward and reverse primers (Table 1) as previously described (Fernando et al., 
2012; Sulentic et al., 2004b). RT-PCR results were compared to a standard curve ranging 
from 1 to 1x10-6 ng/µl of a standard luciferase reporter to determine the lucifererase 
reporter concentration (ng/µl). The amount of transfected plasmid (ng) was calculated 
using the following equation: DNA concentration (ng/µl) x the volume of sample added 
(µl) x the sample fold dilution. Number of plasmids/cell was measured using the equation: 
[ng of plasmid DNA x (plasmid/ng)] / total cells used in DNA isolation. To normalize the 
RLU to transfection efficiency relative to a control (i.e. WT CL-01 cells or a control 
plasmid), the calculated plasmid/cell of each transfected cell population was divided by the 
calculated plasmid/cell of the control to generate a transfection efficiency factor and the 
RLUs of each transfected population was multiplied by the efficiency factor to normalize 
the luciferase activity to transfection efficiency relative to a control plasmid or the WT CL-
01 cells. 
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Primer Primer Sequence 
Luciferase forward primer 5’-ACTGGGACGAAGACGAACACTT-3’ 
Luciferase reverse primer 5’-TCAGAGACTTCAGGCGGTCAA-3’ 
 
Table 1. Primers for the luciferase gene to measure transfection efficiency. Forward 
and reverse primers specific for the luciferase gene. Transfection efficiency is determined 
by measuring using RT-PCR the copies of the luciferase gene in transfected cell 
populations.  
 
Protein Isolation and Western Blot 
 Proteins were isolated by centrifuging cells for 5 minutes at 500 x g then adding 50 
µl of mild lysis buffer (1% NP40, 150 mM NaCl, 2 mM EDTA, 10 mM NaPO4) with 
protease inhibitors (Complete Mini Protease Inhibitor Cocktail; Roche) to the cell pellet. 
For cytoplasmic and nuclear proteins, cells were centrifuged for 5 minutes at 500 x g then 
proteins were extracted using nuclear and cytoplasmic extraction kit (Thermo). Samples 
were frozen and stored at -80oC.  For Western blot analysis, lysates were thawed on ice 
then centrifuged at 14,000 x g for 5 minutes. The supernatants were collected and protein 
concentration was quantified by Bradford protein assay. Equal amounts of protein were 
denatured by heating at 95oC for 5 minutes, and separated by 10% polyacrylamide gel at 
100 volts for about one hour. Proteins were transferred to a polyvinylidene fluoride 
membrane (PVDF) at 300 mAMPs for 2 hours. Membranes were blocked by 1x tris 
buffered saline (TBS) with 5% non-fat milk for 1 to 3 hours at room temperature. After 
that, membranes were probed with primary antibody [rabbit anti-AhR (Santa Cruz, cat# 
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5579) at 1:1000 dilution; mouse anti-β-actin (Cell Signaling, cat# 3700S) at 1:10,000 
dilution; rabbit anti-phospho-Akt (Ser473) (Cell Signaling, cat#4060) at 1:1000 dilution; 
rabbit anti-Akt (pan) (Cell Signaling, cat#4691) at 1:1000; rabbit anti-phospho-Src family 
(Tyr416) (Cell Signaling, cat#2101) at 1:1000; mouse anti-Src (L4A1) (Cell Signaling, 
cat#2110) at 1:1000; mouse anti-GAPDH (Gene Tex, cat#627408) at 1:1000 or mouse anti-
p84 (Gene Tex, cat#70220) at 1:1000], and incubated overnight at 4oC. The membranes 
were washed three times for 5 minutes in TBS with 0.05% tween 20 (TBS-T) and then 
incubated with a secondary antibody conjugated to horseradish peroxidase (HRP); [donkey 
anti-rabbit-HRP 1:20,000 (Promega) or goat anti-mouse-HRP 1:20,000 (Thermo-
scientific)], and incubated on a rotator for one hour at room temperature. Both primary and 
secondary antibodies were diluted in 1x TBS/5% non-fat milk/0.05% tween-20. The 
probed membranes were washed again four times in TBS-T and then exposed to a Super 
Signal West Femto chemiluminescent substrate (Thermoscientific) and analyzed on a 
Chemidoc MP Imager (Biorad). 
RNA Extraction and polymerase Chain Reaction (PCR) 
 RNA was extracted from the cells using Tri-Reagent (Sigma) according the 
manufacturer’s protocol. The RNA was converted to cDNA using a High Capacity cDNA 
Reverse Transcription kit (Applied Biosystems) following the instructions of 
manufacturer. PCR was performed on 100 ng of cDNA using the following: 10x buffer, 
dNTPs, Taq polymerase (New England Biolabs), forward and reverse primers (Table 2) 
and volume was made up to 25 µl with nuclease-free water. PCR products were run on 1% 
agarose gel and analyzed on a Chemidoc MP Imager (Biorad). 
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Primer Primer Sequence 
Annealing 
temperature 
β-actin  
FP: 5’-GCGGATGTCCACGTCACACTTCA-3’ 
RP: 5’-CACCATTGGCAATGAGCGGTTC-3’ 
58oC 
AhR 
FP: 5’- GCACCGATGGGAAATGATAC -3’ 
RP: 5’- TTGACTGATCCCATGTAAGTCTG -3’ 
59oC 
 
Table 2. β-actin and AhR primers for PCR. Forward and reverse primers specific for β-
actin and AHR gene with the annealing temperature. FP- forward primer, RP- reverse 
primer. 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
 CL-01 cells (1.25 x105 cells/ml) were cultured for 96 hours and then centrifuged at 
500 x g for 5 minutes at 40C. The supernatants were transfered into 1.5 ml tubes and stored 
at -80oC for later analysis of secreted Ig. 96-well plates for ELISA were coated at 4oC 
overnight with poly-Ig goat anti-human (GAH) (Southern Biotech, Birmingham, AL) 
diluted to 1:1500 in 0.1M sodium carbonate bicarbonate buffer. Plates were washed three 
times with 1xPBS with 0.05% Tween-20 then four times with dH2O, then blocked with 1x 
PBS with 3% bovine serum albumin (BSA) for 1.5 hours at room temperature. Different 
standard concentrations to generate a standard curve and cell supernatant samples were 
added and incubated in a dry incubator for 1.5 hours at 37oC. Purified IgG (Bethyl 
Laboratories, Montgomery, TX) was used for the standard curve for the IgG ELISA. Plates 
were washed three times with 1xPBS with 0.05% Tween-20 then four times with dH2O 
and then incubated with goat anti-human IgG HRP-conjugated antibody (Bethyl 
Laboratories, Montgomery, TX) at 1:10,000 diluted with 1X PBS with 0.05% Tween 20 
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and 3% BSA for 1.5 hours in a dry incubator at 37oC. after the incubation period, plates 
were washed three times with 1xPBS with 0.05% Tween-20 then four times with dH2O 
then Tetramethylbenzidine (TMB) substrate was added to develop the enzyme reaction. 
The reaction was stopped by adding 4N H2SO4 and the color changed to yellow. 
Absorbance was read with a SpectramaxPlus microplate Spectrophotometer at 450 nM. 
The SOFTmax PRO software was used to calculate the sample Ig concentrations using the 
standard curve.  
CRISPR/Cas9 Gene Editing 
The CRISPR plasmid (pCas-Guide-EF1a-GFP) was purchased from Origene (Rockville, 
MD). The plasmid was cut using the restriction enzymes BamHI and Esp3I (an 
isoschizomer of BsmBI) and the cut plasmid was purified from a 1% agarose gel in 
preparation for cloning the targeting sequences. The targeting sequences specific for the 
human AHR gene (Fig. 9 and table 3) were inserted into the cut plasmid using T4 ligase 
(Promega) and the ligated plasmids were transformed into chemically competent E. coli 
(Zymo). Isolated colonies were plucked from an LB agar plate, grown in a 3 ml culture of 
LB broth, and the plasmids extracted via miniprep (Zymo). The minipreps were screened 
for successful insertion of the targeting sequence by DNA sequencing (Retrogen). When a 
successfully cloned plasmid was identified a transfection-quality preparation of the 
plasmid was created using an endotoxin-free maxiprep kit (Qiagen).  The CRISPR plasmid 
was transfected into CL-01 cells and the transfected cells were allowed to incubate for 72 
hours at a concentration of 1 x 105 cells/ml and were then sorted for GFP expression by the 
Research Flow Cytometry Core at Cincinnati Children’s Hospital. Cells expressing GFP 
were seeded into a 96-well plate at 1 cell/well. When the cells outgrew the 96-well plate, 
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they were transferred to a 24-well plate. When sufficient cell numbers were achieved, a 
portion of the cells were collected for protein, DNA and RNA analysis. 
 
 
Figure 9. The human AHR gene with CRISPR targets. The targeting sequence for 
CRISPR plasmid 1 (T1) and 2 (T2) are in exon 1, and CRISPR plasmid 3 (T3) is in exon 
2 of the AHR gene. Basic helix–loop–helix domain (bHLH); ligand binding domain (LBD); 
Per/Arnt/Sim domain (PAS) and transactivation domain (TAD). 
 
Target # CRISPR Target Targeting Sequence 
T1 AhR exon 1, 24-43F AGTAGCCGCCGCCGTCGGCT 
T2 AhR exon 1, 73-92F TCACCTACGCCAGTCGCAAG 
T3 AhR exon 2, 45-64RC AAGTCGGTCTCTATGCCGCT 
 
Table 3. CRISPR/Cas9 targeting sequences. These targeting sequences were cloned into 
the CRISPR plasmids following the manufacturer’s (Origene) instructions. 
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Statistical Analysis 
Comparisons between treatment groups were analyzed using a 1-way ANOVA followed 
by a Dunnett’s Multiple Comparison test. GraphPad Prism software was used to determine 
significant differences between treatment groups (mean ± SEM) and the corresponding 
vehicle control as represented by “*”, “**”, “***” at p<0.05, p<0.01 and p<0.001, 
respectively. Significant differences between clones and WT clone were denoted by †, †† 
and †††, at p<0.05, p<0.01 and p<0.001, respectively.  Comparisons between treatment 
groups and VH of each time point were analyzed using a two-way ANOVA followed by a 
Bonferroni post-tests, significant differences were denoted by “*”, “**”, “***” which 
represents significance at p<0.05, p<0.01 and p<0.001, respectively. Significant 
differences between AhRA groups and AhRA plus TCDD were denoted by “#”, “##”, 
“###”, at p<0.05, p<0.01 and p<0.001, respectively. 
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III RESULTS 
The role of the AhR on the activation of cytosolic signaling proteins. 
 Previous studies in a mouse B-cell line stimulated with LPS demonstrated a 
concentration-dependent inhibition of IgM secretion (Sulentic et al., 1998). In another 
study using human primary B cells, TCDD reduced IgM expression in nine of twelve 
human donors while having no effect in two donors and enhancing IgM expression in one 
donor (Lu et al., 2010). In a previous study in our lab, using a human B-cell line that can 
be induced to secrete antibodies, IgM secretion was fairly unresponsive to treatment with 
TCDD or the AhRAs CH223191 or 6,2’,4’,-trimethoxyflavone (TMF) (Panstingel 2017, 
unpublished data). In contrast, IgG secretion was inhibited by TCDD and surprisingly 
increased by AhRA. Moreover, TCDD inhibited the induction of Cγ1-4 germline/functional 
transcripts while the AhRA alone increased all of the Cγ1-4 germline/functional transcripts 
(Burra 2015, unpublished data). Our lab has also used shRNA to target and degrade AhR 
mRNA and knockdown (KD) the AhR protein levels. IgM secretion was unaffected by 
AhR KD, whereas IgG levels were nearly eliminated with AhR KD. Treatment with the 
AhRA had little effect on IgG secretion in the AhR KD cells suggesting that the AhRA 
effect is AhR dependent (Kashgari 2015, unpublished data). These data suggest a 
physiological role of the AhR (independent of ligand) on IgG expression and that the 
AhRA may induce a conformational change in the cytosolic AhR that results in an 
activation of other signaling proteins. The AhRA prevents translocation of the AhR into 
the nucleus and inhibits its activation (Kim et al. 2006) but binding of the AhRA could 
influence interaction of the AhR with other cytosolic proteins to lead to the increase in IgG 
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secretion. Therefore, the objective of these studies was to determine if AhRA treatment 
activated cytosolic signaling pathways known to play a role in B-cell differentiation and Ig 
production and previously shown to interact with the AhR.  
 Previous studies in our lab has shown AhR binding to DRE in the mouse hs1.2 and 
hs4 enhancers of the 3’IghRR following TCDD treatment (Sulentic et al., 2000; Salisbury 
& Sulentic, 2015). Interestingly, our human B-cell line model (CL-01) is heterozygous for 
the AhR and expresses a non-functional transactivation domain in one of its alleles due to 
three SNPs (Kashgari 2015, unpublished data) that could decrease the functional activity 
of the AhR. In this study, CL-01 cells were transfected with a DRE reporter and treated 
with TCDD and/or AhRA (Fig. 10). While TCDD treatment alone had no effect on DRE 
activity, AhRA at 10 µM nearly completely inhibited basal DRE activity, which was 
partially reversed by 30 nM TCDD reversed the inhibitory effect of AhRA (Fig. 10). These 
results suggest a high basal activity of the DRE reporter that is AhR-dependent. The AhRA 
prevents translocation of the AhR into the nucleus and inhibits its binding to DRE motifs 
while TCDD competes with the AhRA for binding to the AhR in the cytosol and increases 
AhR translocation into nucleus. The unexpectedly high basal activity of the DRE suggests 
either basal translocation of the AhR perhaps via an unknown endogenous ligand or 
increased activity of the SV40 promoter. To determine if either was responsible for the 
high basal activity of the DRE reporter, first a luciferase reporter containing only the SV40 
promoter (without DRE motifs) was used to compare its basal activity with the DRE 
reporter. The result showed that the SV40 reporter plasmid had very low luciferase activity 
compared to the DRE reporter activity (Fig. 11), indicating that the increase in DRE 
reporter activity was mediated by the transcriptional activity of the DRE binding sites and 
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not from high basal activity of the SV40 promoter. This suggest that the basal activity of 
the DRE reporter could be from nuclear AhR. Therefore, the cytosolic and nuclear AhR 
was evaluated by Western blot analysis. Human CL-01 cells were treated with TCDD and 
AhRA. After cultured the cells for 24 hours, the cells were collected and lysed by cytosolic 
lysate buffer and transferred the supernatant containing the cytosolic proteins into new 
tubes. The nuclear pellets were lysed with nuclear lysate buffer in order to extract nuclear 
proteins. Both cytosolic and nuclear extractions were examined for AhR protein (Fig. 12). 
The Western blot identified nuclear AhR in naïve cells, which may account for the high 
basal activity of the DRE reporter. 
 Src protein kinase is associated specifically with the cytosolic AhR complex along 
with hsp90 and upon ligand binding to the AhR, Src is activated and released from the 
complex (Enan & Matsumura, 1996). Since the AhRA competes with TCDD for binding 
to the AhR, and then prevents the AhR from translocating to the nucleus (Kim et al. 2006), 
we hypothesized that AhRA binding also results in Src disassociation and activation in the 
human CL-01 B cells. Human CL-01 B cells were stimulated with R848 and treated with 
AhRA for different time points (5 min, 15 min, 30 min, 2 h and 24 h). At each time point, 
cells were collected and lysed in order to extract proteins and examine for Src 
phosphorylation. Phospho-Src (Y416) antibody has been used to detect Src phosphorylated 
at tyrosine 416, which is located in the activation loop and required for optimal activity of 
Src (Frame, 2002). Most previous studies have used phospho-Src (Y416) antibody to detect 
activated Src kinase in Western blot analysis (Dong et al., 2011), including human B cells 
(Ye et al., 2016). Unexpectedly, phospho-Src was not detected at any time point, with or 
without cellular stimulation and AhRA treatment (Fig. 13), suggesting that the R848 
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stimulation does not induce phosphorylation of Src, which may require other stimulation 
such as BCR activation. 
 The Akt signaling pathway plays a crucial role in multiple cellular processes, 
including cell proliferation, angiogenesis, metabolism, differentiation and survival. Basal 
expression of phospho-Akt was observed in a Burkitt lymphoma cell line under untreated 
conditions (Huang et al., 2012). Many studies have showed that AhR regulates Akt 
activation (Wu et al., 2007; Al-Dhfyan et al., 2017). These studies indicate that Akt kinase 
is activated during B-cell differentiation and class switching. As the AhRA keeps the AhR 
in the cytoplasm and prevents its translocation into the nucleus, we suspected the AhRA 
could increase Akt activity. Western blot analysis showed that Akt is basally 
phosphorylated in CL-01 cells (Fig. 14A) but after 30 minutes of AhRA and R848 co-
treatment, Akt phosphorylation significantly increased and at 2 hours returned to basal 
phosphorylation level (Fig. 14B). This indicates that the cytosolic AhR could activate the 
Akt pathway after 30 minutes of AhRA treatment, which might lead to increase IgG 
production. 
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Figure 10. Concentration-dependent decrease of DRE reporter activity by AhRA. A. 
The DRE luciferase reporter has six DRE binding sequences inserted into a pGL3 
luciferase reporter with a SV40 promoter. B. CL-01 cells were transiently transfected with 
the DRE reporter, and were either cultured in the absence of any additional treatment 
(naïve, NA) or with the vehicle control (VH, 0.01% DMSO), TCDD (30nM) or AhRA 
(0.01, 0.1, 1, 10 µM), then incubated at 37oC for 24 hours. Luciferase enzyme activity is 
represented on the y-axis as relative light units (RLU). Comparisons between the treatment 
groups were analyzed using a two-way ANOVA followed by a Bonferroni post-tests. 
Significant differences between treatment groups and VH were denoted by ** and ***, 
which represents significance at p<0.01 and p<0.001, respectively. Significant differences 
between AhRA groups and AhRA+30nM TCDD were denoted by ## and ###, which 
represents significance at p<0.01 and p<0.001, respectively. Results are representative of 
three independent experiments (mean SEM, n=3). 
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Figure 11.  Low SV40 reporter activity compared to DRE reporter activity. CL-01 
wild type (WT) cells were transiently transfected with the DRE reporter or SV40 reporter, 
and were either cultured in the absence of any additional treatment (naïve, NA) or with the 
vehicle control (VH, 0.01% DMSO) or TCDD (30 nM), then incubated at 37oC for 24 
hours. Comparisons between the treatment groups were analyzed using a one-way 
ANOVA followed by a Dunnett’s Multiple Comparison post-test. Results are 
representative of three independent experiments (mean SEM, n=3). 
 
 
 
Figure 12. Nuclear AhR in naïve cells. CL-01 cells were cultured without further 
treatment naïve (NA) or treated with vehicle (VH, 0.01% DMSO), 10 µM AhRA (A) or 
both AhRA and 30 nM TCDD (A+T). Whole cells (C), cytoplasmic and nuclear proteins 
were isolated. 30 μg of proteins were subjected to Western blot analysis. All membranes 
were probed with antibodies specific for AhR (122 kDa), p84 (84 kDa, nuclear loading 
control) or GAPDH (37 kDa, cytoplasmic loading controls). Results are representative of 
three independent experiments. 
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Figure 13. The AhRA has no effect on Src activation. CL-01 cells were cultured without 
treatment naïve (NA) or stimulated with 1µg/ml R848 (C), R848 plus vehicle 0.01% 
DMSO (VH) or R848 plus 10 µM AhRA (A). Cells were lysed with mild lysis buffer 
containing protease and phosphatase inhibitors at different time points (5 min, 15 min, 30 
min, 2 h, 24 h). 30 μg of proteins were subjected to Western blot analysis. All membranes 
were probed with antibodies specific for phospho-Src (60 kDa), Src (60 kDa) or β-actin 
(42 kDa). Src and β-actin served as loading controls. Results are representative of three 
independent experiments. 
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Figure 14. The AhRA increases Akt activity after 30 minutes. A. CL-01 cells were 
cultured without treatment naïve (NA) or stimulated with 1µg/ml R848 (C), R848 plus 
vehicle 0.01% DMSO (VH) or R848 plus 10 µM AhRA (A). Cells were lysed with mild 
lysis buffer containing protease and phosphatase inhibitors at different time points (5 min, 
15 min, 30 min, 2 h, 24 h). 30 μg of proteins were subjected to Western blot analysis. All 
membranes were probed with antibodies specific for phospho-Akt (60 kDa) or β-actin (42 
kDa), which served as loading controls. B. Densitometric estimation of expression was 
graphically represented for phospho-Akt. Fold change normalized to the corresponding VH 
in each time point. Results are representative of three independent experiments (mean  
SEM, n=3). Comparisons between the treatment groups were analyzed using a two-way 
ANOVA followed by a Bonferroni post-tests. Significant differences between treatment 
groups and VH were denoted by (*), which represents significance at p<0.05.  
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 In B-lymphocytes, the 3’IGHRR enhancers contain numerous transcription factor-
binding sites within hs1.2 and hs4 enhancers. The hs1.2 enhancer is polymorphic due to 
the potential of having one to four 55 bp invariant sequences. The invariant sequence 
contains a DRE, NFκB, SP-1, NF-1 and AP-1 binding site (Pinaud et al., 2011). Because 
of the important role of NFκB in B-cell activation and activity of the mouse 3’IghRR, we 
measured NFκB transcriptional activity using a luciferase reporter plasmid that has three 
consensus NFκB binding motifs. CL-01 cells were transfected with the NFκB reporter 
plasmid then stimulated with R848. and treated with 30nM TCDD and 10µM AhRA. As 
expected of a TLR ligand, R848 stimulation significantly increased NFκB activity but 
TCDD and AhRA had no effect on NFκB activity (Fig. 15). The AhRA and TCDD do not 
appear to influence any interaction between the AhR and NFκB pathways. 
 AP-1 is another transcription factor binding site in the hs1.2 enhancer of the 
3’IGHRR (Pinaud et al., 2011). Since it plays an important role in B-cell differentiation, 
we utilized a luciferase reporter with three AP-1 binding motifs to measure the 
transcriptional activity of AP-1. The CL-01 cells were transfected with the AP-1 plasmid 
then stimulated with 1 µg/ml R848 and treated with 30nM TCDD or 10µM AhRA. AP-1 
activity was not affected by TCDD or AhRA in either stimulated nor unstimulated cells. 
Surprisingly, R848 stimulation decreased AP-1 transcriptional activity (Fig. 16). This 
result suggests that AP-1 does not mediate an increase in IgG production by R848 
stimulation or AhRA and the AhRA does not disrupt the activation of AP-1 pathway 
proteins like fos and jun proteins. 
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Figure 15. The AhRA and TCDD had no effect on NFκB activation. A. The NFκB 
luciferase reporter plasmid construct which contains three κB motifs conjugated within a 
Conalbumin A promoter (ConA). B. CL-01 cells were transiently transfected with the 
NFκB plasmid and incubated for 24 hours at 37oC. Transfected cells were stimulated with 
R848 (1 μg/ml) in all groups except naïve (NA) and vehicle (VH, 0.01% DMSO). Cells 
were stimulated with R848 alone (C) or with the vehicle control (VH, 0.02% DMSO), 
TCDD (30nM), or AhRA (10µM). Luciferase enzyme activity is represented on the y-axis 
as relative light units (RLU). Results are representative of three independent experiments 
(mean SEM, n=3). Comparisons between the treatment groups were analyzed using a one-
way ANOVA followed by a Dunnett’s Multiple Comparison post-test. Significant 
differences between stimulated VH and VH alone were denoted by ***, which represents 
significance at p<0.001. 
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Figure 16. The AhRA and TCDD have no effect on AP-1 activity but cellular 
stimulation inhibits it. A. The AP-1 luciferase reporter has three AP-1 binding sequences 
inserted into a pGL3 luciferase reporter with a SV40 promoter. B. CL-01 cells were 
transiently transfected with the AP-1 plasmid and incubated for 24 hours at 37oC. 
Transfected cells were incubated in absent of treatments naïve (NA) or treated with vehicle 
(VH, 0.01% DMSO), TCDD (30nM) or AhRA (10µM). Cells were stimulated with R848 
alone (C) or with the vehicle control (VH, 0.02% DMSO), TCDD (30nM), or AhRA 
(10µM). Results are representative of three independent experiments (mean SEM, n=3). 
Comparisons between the treatment groups were analyzed using a one-way ANOVA 
followed by a Dunnett’s Multiple Comparison post-test. Significant differences between C 
group and unstimulated VH group were denoted by (*), which represents significance at 
p<0.05. 
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Differential effects of TCDD and AhR antagonist on the human 3’IGHRR in CL-01 
cells. 
 B-cell stimulation would be expected to increase the activity of the 3’IGHRR 
enhancers since B-cell stimulation is known to increase the transcriptional activity of the 
IGH gene, which is at least partially driven by the 3’IGHRR based on mouse studies. 
TCDD treatment was expected to result in reduced activity of the plasmids since TCDD is 
known to act as an immunosuppressant in both mouse and human B cells. The 
transcriptional activity of mouse 3’IghRR in mouse CH12.LX cells was increased with 
LPS stimulation, and inhibited when stimulated cells were co-treated with TCDD (Sulentic 
et al., 2004a). The human 3’IGHRR activity has been evaluated in human CL-01 cells and 
mouse CH12.LX cells in response to B-cell stimulation or TCDD. The CH12.LX cells 
transfected with human 3’IGHRR showed more sensitivity to TCDD as well as LPS 
stimulation. The human 3’IGHRR activity was induced by LPS and inhibited by TCDD, 
which is similar to the effect on the mouse 3’IghRR activity. By contrast, 3’IGHRR activity 
in the human CL-01 cell line with either the VH  promoter or the intronic promotors Iγ3 or 
Iε exhibited variable and statistically insignificant change in response to TCDD or 
stimulation (R848 or CD40L plus IL-4) (Alfaheeda 2016, unpublished data). In another 
study with CL-01 cells, there was no upregulation of CYP1A1 mRNA expression in 
response to TCDD (Burra 2015, unpublished data). Consequently, these results suggested 
that the AhR in the CL-01 cells might be not functional. As described above, sequence 
analysis found that the AhR is heterozygous in CL-01 cells, likely with a non-functional 
transactivation domain in one of its alleles due to the presence of three SNPs (P517S, 
R554K, and V570I) in Exon 10 (Kashgari 2015, unpublished data). Exon 10 encodes the 
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transactivation domain that regulates expression of other genes (Harper et al. 2002). These 
SNPs were demonstrated to impair the ability of CYP1A1 induction by TCDD (Wong et 
al., 2001). Therefore, we hypothesized that the lack of sensitivity of the 3’IGHRR to TCDD 
is due to not having two AhR alleles with functional transactivation domains. Our lab used 
CRISPR/Cas9 gene editing to target the AhR gene with the goal of inducing an insertion 
or deletion mutation to prevent AhR gene expression. After screening and characterizing 
many clones, a small number of clones appeared to have a monoallelic knockout of the 
AhR based on Western analysis and DRE reporter inducibility by TCDD. Further analysis 
was conducted on one clone that appeared to have a monoallelic knockout and expressed 
an AhR with a functional transactivation domain (AhR TA) (Panstingel 2017, unpublished 
data). As demonstrated above in Fig. 10, TCDD treatment did not induce the 6x DRE 
reporter in CL-01 wild type cells but in the monoallelic knockout clone, TCDD induced 
the DRE reporter (Fig. 17). This suggests that the CL-01 wild type cells may express a 
dominant negative AhR due to the heterozygous presence of SNPs in the transactivation 
domain of the AhR (Kashgari 2015, unpublished data). 
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Figure 17. TCDD induced the DRE reporter in CL-01 cells targeted for AhR gene 
editing by CRISP/Cas9. A. CL-01 WT cells were transiently transfected with the DRE 
reporter plasmid and cultured for 24 hours. B. CL-01 AhR TA cells were transiently 
transfected with the DRE reporter plasmid and cultured for 24 hours. All transfected cells 
were either cultured in the absence of any additional treatment (naïve, NA) or treated with 
the vehicle control (VH, 0.01% DMSO) or 30 nM TCDD. The graphs on the left represent 
luciferase activity as relative light units (RLU) and graphs on the rights represent the fold 
change in luciferase activity compared to VH control that was generated from averaging 
the means of three independent experiments. Comparisons between the treatment groups 
were analyzed using a one-way ANOVA followed by a Dunnett’s Multiple Comparison 
post-test. Significant differences between treatment groups and VH were denoted by *, 
which represents significance at p<0.05. (mean SEM, n=3). 
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 To determine if the sensitivity of the 3’IGHRR to TCDD is dependent on the AhR 
transactivation domain, 3’IGHRR luciferase reporters were transfected into CL-01 WT 
cells and CL-01 AhR TA cells, which appear to express a transactivation functional AhR. 
There was little to no effect of CD40L plus IL-4 stimulation or TCDD treatment on 
3’IGHRR activity with the VH promoter in both CL-01 WT cells and CL-01 AhR TA cells 
(Fig. 18).  Additionally, we evaluated the effect of stimulation and TCDD on the 3’IGHRR 
when linked with the intronic promoters Iγ3 or Iε. The intronic promoters are involved in 
promoting CSR and may interact more with the 3’IGHRR as compared to the VH promoter 
(Bottaro 1997, Stavnezer 1996). Moreover, the Iγ3 promoter has a DRE core motif that the 
AhR could bind to and mediate a TCDD effect. Additionally, the Iε promoter has IL-4 
binding sites that should make this promoter more sensitive to CD40L plus IL4 stimulation 
(Delphin, 1995). Interestingly, in both CL-01 WT and AhR TA cells, stimulation and 
TCDD had no effect on 3’IGHRR activity when linked to either intronic promoter (Fig. 19 
and 20). 
 As discussed above, our lab found that co-treatment of stimulation (CD40L plus 
IL-4) and AhRA increased the secretion of IgG while TCDD inhibited IgG secretion (Burra 
2015, unpublished data). Therefore, the effect of the AhRA on each of the 3’IGHRR 
reporter was also analyzed. The VH-3’IGHRR reporter showed no consistent effect of 
AhRA treatment in both CL-01 WT and CL-01 AhR TA cells (Fig. 18). In addition, both 
CL-01 Cells transfected with the Iγ3-3’IGHRR reporter showed an increase in activity with 
AhRA (Fig. 19 and 20), which is compatible with previous results that AhRA increased 
the secretion of IgG (Burra 2015, unpublished data). In the plasmid driven by Iε-3’IGHRR 
there was an increase in activity in both CL-01 WT and AhR TA cells with AhRA. 
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Therefore, AhRA have the same effect on 3’IGHRR activity in both CL-01 wild type and 
CL-01 AhR TA. These results indicate that the dysfunction of the AhR transactivation 
domain in the CL-01 wild type has no effect on the sensitivity of the 3’IGHRR to TCDD 
or AhRA since it has the same effects as in CL-01 cells expressing only an AhR with a 
functional transactivation domain. 
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Figure 18. TCDD and AhRA have no effect on VH-3’IGHRR reporter activity in CL-
01 WT and AhR TA cells. A. VH-3’IGHRR luciferase plasmid construct. B. CL-01 WT 
cells. C. CL-01 AhR TA cells. All cells were transiently transfected with VH-3’IGHRR 
plasmid and cultured for 48 hours. Cells were either cultured in the absence of any 
treatment (naïve, NA) or treated with CD40L plus IL-4 stimulation alone (C) or co-
treatment stimulation with vehicle control (VH, 0.01% DMSO), 30 nM TCDD, 10 µM 
AhRA or TCDD plus AhRA (T+A). The graphs on the left represent luciferase activity as 
relative light units (RLU) and graphs on the rights represent the fold change in luciferase 
activity compared to VH control that was generated from averaging the means of at least 
three independent experiments. Comparisons between the treatment groups were analyzed 
using a one-way ANOVA followed by a Dunnett’s Multiple Comparison post-test.  
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Figure 19. Iγ3-3’IGHRR reporter activity is not effected by TCDD but increased by 
AhRA in both CL-01 WT and AhR TA cells. A. Iγ3-3’IGHRR luciferase plasmid 
construct. B. CL-01 WT cells. C. CL-01 AhR TA cells. All cells were transiently 
transfected with Iγ3-3’IGHRR plasmid and cultured for 48 hours. Cells were either cultured 
in the absence of any treatment (naïve, NA) or treated with CD40L plus IL-4 stimulation 
alone (C) or co-treatment stimulation with vehicle control (VH, 0.01% DMSO), 30 nM 
TCDD, 10 µM AhRA or TCDD plus AhRA (T+A). The graphs on the left represent 
luciferase activity as relative light units (RLU) and graphs on the rights represent the fold 
change in luciferase activity compared to VH control that was generated from averaging 
the means of at least three independent experiments. Comparisons between the treatment 
groups were analyzed using a one-way ANOVA followed by a Dunnett’s Multiple 
Comparison post-test. Significant differences between treatment groups and VH were 
denoted by * and **, which represents significance at p<0.05 and p<0.01, respectively. 
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Figure 20. Iε-3’IGHRR reporter activity is not effected by TCDD but increased by 
AhRA in both CL-01 WT and AhR TA cells. A. Iε-3’IGHRR luciferase plasmid 
construct. B. CL-01 WT cells. C. CL-01 AhR TA cells. All cells were transiently 
transfected with Iε-3’IGHRR plasmid and cultured for 48 hours. Cells were either cultured 
in the absence of any treatment (naïve, NA) or treated with CD40L plus IL-4 stimulation 
alone (C) or co-treatment stimulation with vehicle control (VH, 0.01% DMSO), 30 nM 
TCDD, 10 µM AhRA or TCDD plus AhRA (T+A). The graphs on the left represent 
luciferase activity as relative light units (RLU) and graphs on the rights represent the fold 
change in luciferase activity compared to VH control that was generated from averaging 
the means of at least three independent experiments. Comparisons between the treatment 
groups were analyzed using a one-way ANOVA followed by a Dunnett’s Multiple 
Comparison post-test. Significant differences between treatment groups and VH were 
denoted by * and **, which represents significance at p<0.05 and p<0.01, respectively. 
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AhR knockout abrogates IgG secretion 
 In a mouse B-cell line (CH12.LX) stimulated with LPS, TCDD decreased IgM 
secretion, whereas it did not affect IgM secretion in an AhR-deficient B-cell line (BCL-1) 
suggesting that the AhR plays an important role in inhibition of IgM secretion by TCDD 
(Sulentic et al., 1998). Moreover, AhR knockdown by shRNA or inhibition by an AhR 
antagonist reversed TCDD-induced inhibition of IgA secretion but did not alter basal or 
stimulation-induced IgA secretion in CH12.LX cells (Wourms & Sulentic, 2015). Another 
study with AhR-/- mice showed normal immune function and Ig production after treatment 
with TCDD (Vorderstrasse et al., 2001). These provide evidence that the AhR mediates 
TCDD-induced inhibition of Ig and B-cell differentiation but it is not required for normal 
immune function (Wourms & Sulentic, 2015; Vorderstrasse et al., 2001). However, in a 
human B-cell line, our lab previously used shRNA to knockdown the AhR and found a loss 
of IgG secretion with knockdown of the AhR. In contrast, TCDD inhibited IgG secretion 
in wild type cells and the AhR antagonist increased IgG expression (Kashgari 2015, 
unpublished data). Therefore, the objective of the current studies was to confirm the shAhR 
knockdown results by generating a stable knockout of the AhR in the CL-01 cells using 
CRISPR-Cas9 gene editing. The CL-01 cells were transfected with CRISPR vectors 
expressing GFP and guide RNA targeting sequences in exon 1 or in exon 2 of the AhR 
gene (Table 3). After sorting GFP+ cells and seeding one cell per well, 284 clones were 
grown and screened for AhR expression by Western blot (data not shown). Only three 
clones (10F10, 7C8, 8F7) demonstrated low expression of the AhR by Western analysis 
(Fig. 21), and they targeted exon 2.  These three clones were tested by PCR for AhR mRNA 
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expression. Two clones (10F10, 8F7) showed decreased AhR mRNA expression while one 
clone (7C8) showed very low expression (Fig. 22).  
 Since IgG levels were nearly eliminated with AhR KD (Kashgari 2015, 
unpublished data) as mentioned above, IgG secretion was evaluated by ELISA in the 
CRISPR/Cas9 clones. Cells were stimulated with R848 and treated with TCDD then 
incubated for 96 hours. As previously seen with AhR knockdown by shRNA IgG secretion 
in the CRISPR/Cas9 clones was not induced with stimulation (Fig. 23). These results 
suggest a physiological role of the AhR in IgG expression. 
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Figure 21. AhR expression in clones transfected with CRISPR-Cas9 targeting the 
exon 2 in the AHR gene. CL-01 wild type (WT) and 8 CRISPR-Cas9 clones were lysed 
with mild lysis buffer and 40 μg of protein was subjected to Western blot analysis. All 
membranes were probed with AhR antibody (122 kDa) and anti-β-actin (42 kDa), which 
served as the loading control. Result is representative of three independent experiments. 
 
 
Figure 22. AhR mRNA expression in CRISPR-Cas9 clones showing decreased AhR 
protein levels. RNA was isolated from CL-01 wild type (WT) and the clones 10F10, 7C8 
and 8F7. RNA was converted by reverse transcription into cDNA and 100 ng of cDNA 
was amplified using AhR and β-actin primers (Table2). Product size for AhR is 549 bp and 
β-actin is 224 bp. Results are representative of three independent experiments. 
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Figure 23. Low IgG secretion in CRISPR/Cas9 clones compared to WT. WT and 
CRISP/Cas9 clones (10F10, 7C8 and 8F7) were cultured without treatment naïve (NA) or 
stimulated with 1 µg/ml R848 (C) and treated in addition to R848 with the vehicle control 
0.02% DMSO (VH) or 30nM TCDD. Cells were incubated for 96 hours, then supernatant 
collected and analyzed for IgG secretion by ELISA. Results are representative of three 
independent experiments (mean SEM, n=3). Comparisons between the treatment groups 
were analyzed using a one-way ANOVA followed by a Dunnett’s Multiple Comparison 
post-test. Significant differences between treatment groups and VH were denoted by *, 
which represents significance at p<0.05, respectively. 
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 Interestingly, the 10F10 and 8F7 clones appeared to change in the expression level 
of the AhR over time. Within about 5 months between the initial analysis and the last 
analysis and after about 6 new thaws, Western analysis showed an increased expression of 
the AhR in 10F10 and 8F7 while the 7C8 clone still had low AhR expression (Fig. 24). In 
addition, AhR mRNA expression was increased in the 10F10 and 8F7 clones while the 7C8 
clone still had low expression (Fig. 25). The next step was to evaluate the TCDD effects 
on DRE reporter in these clones. TCDD induced the DRE reporter in the 10F10 and 8F7 
clones while it did not affect the DRE activity in 7C8 clone (Fig. 26). These data suggest 
a monoallelic edit in the 10F10 and 8F7 clones disrupting the AhR allele that has a non-
functional transactivation domain, resulting in decreased AhR expression. Over time, the 
functional AhR allele appears to compensate for the decrease in AhR expression and 
returns it to normal expression level. The 7C8 clone showed stable AhR knockdown 
suggesting that CRISPR/Cas9 edited and disrupted both AhR alleles.  
 To evaluate the role of the AhR in the effects of the TCDD and AhRA on 3’IGHRR 
activity, CRISPR/Cas9 clones were transfected with the Iγ3-3’IGHRR reporter plasmid. 
Transfected cells were stimulated with CD40L plus IL4 and treated with TCDD and AhRA. 
TCDD had no effect on the CRISPR/Cas9 clones while the AhRA increased Iγ3-3’IGHRR 
reporter activity in the high AhR expression clones, 10F10 and 8F7. In contrast, the AhR 
knockdown clone 7C8 was not effected by AhRA (Fig. 27). These results are compatible 
with previous results that AhRA increased the secretion of IgG (Burra 2015, unpublished 
data) and that IgG expression is dependent on the AhR (Fig. 26 and Kashgari 2015, 
unpublished data). To determine if the basal activity of the 3’IGHRR reporters is affected 
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by loss of the AhR, the RLUs were normalized to transfection efficiency. The clones 
(10F10 and 8F7) with high AhR expression demonstrated significantly increased basal 
activity of both the VH-3’IGHRR and Iγ3-3’IGHRR reporter plasmids compared to the WT 
while the 7C8 clone had similar basal activity as the WT cells (Fig. 28). 
 
 
Figure 24. Increased AhR expression in the 10F10 and 8F7 clones. CL-01 wild type 
(WT) and CRISPR/Cas9 clones were lysed with mild lysis buffer and 40 μg of protein was 
subjected to Western blot analysis. All membranes were probed with antibodies specific 
for AhR (122 kDa) and anti-β-actin (42 kDa), which served as the loading control. Results 
are representative of three independent experiments 
 
 
Figure 25. AhR mRNA expression was increased in 10F10 and 8F7 clones. RNA was 
isolated from CL-01 wild type (WT) and the clones 10F10, 7C8 and 8F7. RNA was 
converted by reverse transcription into cDNA and 100 ng of cDNA was amplified using 
AhR and β-actin primers (Table2). Product size for AhR is 549 bp and β-actin is 224 bp. 
Results are representative of three independent experiments 
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Figure 26. TCDD increased the DRE reporter activity in 10F10 and 8F7 clones but 
not in the 7C8 clone. (A) 10F10 clone. (B) 7C8 clone. (C) 8F7 clone. Cells were 
transiently transfected with DRE plasmid then cells were either cultured in the absence of 
any additional treatment (naïve, NA) or with 0.01% DMSO vehicle control (VH) and 30nM 
of TCDD, and then incubated at 37oC for 24 hours. The graphs on the left represent 
luciferase activity as relative light units (RLU) normalized to transfection efficiency and 
graphs on the rights represent the fold change in luciferase activity compared to VH control 
that was generated from averaging the means of at least three independent experiments. 
Comparisons between the treatment groups were analyzed using a one-way ANOVA 
followed by a Dunnett’s Multiple Comparison post-test. Significant differences between 
treatment groups and VH were denoted by ** and ***, which represents significance at 
p<0.01 and p<0.001, respectively. (mean SEM, n=3) 
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Figure 27. Iγ3-3’IGHRR reporter activity in the AhR knockdown clone 7C8 was not 
effected by AhRA.  CL-01 WT and CRISPR/Cas9 clones were transiently transfected with 
Iγ3-3’IGHRR plasmid and cultured for 48 hours. Cells were either cultured in the absence 
of any treatment (naïve, NA) or treated with CD40L plus IL-4 stimulation alone (C) or co-
treatment stimulation with vehicle control (VH, 0.01% DMSO), 30 nM TCDD, 10 µM 
AhRA or TCDD plus AhRA (T+A). Results are representative of three independent 
experiments (mean SEM, n=3). Comparisons between the treatment groups were analyzed 
using a one-way ANOVA followed by a Dunnett’s Multiple Comparison post-test. 
Significant differences between treatment groups and VH were denoted by * and **, which 
represents significance at p<0.05 and p<0.01, respectively. 
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Figure 28. The 3’IGHRR basal reporter activities are high in 10F10 and 8F7 clones 
but not in 7C8 clone.  CL-01 WT and CRISPR/Cas9 (10F10, 7C8 and 8F7) clones were 
transiently transfected with Iγ3-3’IGHRR or VH-3’IGHRR plasmid and cultured for 48 
hours. Results are representative of three independent experiments (mean SEM, n=3). 
Numbers above bars represented the fold-change to the WT clone. Comparisons between 
clones were analyzed using a one-way ANOVA followed by a Dunnett’s Multiple 
Comparison post-test. Significant differences between clones and WT clone were denoted 
by †† and †††, which represents significance at p<0.01 and p<0.001, respectively.  
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IV DISCUSSION 
 The TCDD and AhR mechanisms in inhibition of Ig expression in humans are not 
clear yet. In a human B cell line, IgG secretion is inhibited in response to TCDD but 
increased about two-fold when the B cells are treated with an AhRA [CH223191 or 
6,2’,4’,-trimethoxyflavone (TMF)] (Burra 2015; Panstingel 2017, unpublished data). In 
addition, AhR knockdown by shRNA eliminated IgG secretion (Kashgari 2015, 
unpublished data). Other studies have shown that AhR can bind to other transcription 
factors like SP1, NF-κB and AP-1 (Suh et al., 2002; Tian et al., 1999; Kobayashi et al., 
1996). These data suggest a physiological role of the AhR on IgG expression and that the 
AhRA may induce non-genomic effects mediated by the cytosolic AhR that result in 
activation of other signaling proteins. 
 In this study, we determined the activity of the AhR using the DRE reporter. The 
DRE reporter plasmid showed highly basal activity and AhRA nearly completely inhibited 
this activity, while TCDD reversed the inhibitory effect of AhRA. This suggest a high basal 
activity of the DRE reporter that is AhR-dependent. The basal activity of the DRE reporter 
is mediated by the transcriptional activity of the DRE binding sites and not from high basal 
activity of the SV40 promoter. In addition, Western analysis showed the presence of 
nuclear AhR in naive cells that could be responsible for the increased basal activity of the 
DRE reporter. A portion of the AhR could be localized in the nucleus independent of ligand 
activation or an endogenous ligand may promote a low level of basal AhR activation.  
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 Additionally, TCDD treatment alone had no effect on DRE reporter activity in the 
human CL-01 cells that is very different from mouse B cells in which TCDD enhanced the 
AhR binding to DRE sites (Wourms & Sulentic, 2015). In CL-01 human B cells, it was 
found that the AhR is heterozygous, likely with a non-functional transactivation domain in 
one of its alleles due to the identification of three SNPs (P517S, R554K, and V570I) present 
in Exon 10 (Fig. 29) (Kashgari 2015, unpublished data). Exon 10 is a region encoding the 
transactivation domain that regulates expression of genes sensitive to the AhR (Harper et 
al. 2002). Moreover, These SNPs were demonstrated to impair the ability of CYP1A1 
induction by TCDD (Wong et al., 2001). Therefore, the low AhR activity could be due to 
a nonfunctional transactivation domain in one of the AhR alleles (Kashgari 2015, 
unpublished data). Notably, these exon 10 SNPs do not affect the ligand binding affinity 
to the AhR (Harper et al., 2002). And should not affect the potential non-genomic function 
of the AhR. Non-genomic functions could be mediated by  protein-protein interactions 
between the AhR and regulatory proteins such as Src protein kinase and NFκB (Enan and 
Matsumura, 1996; Tian et al., 1999). Moreover, the AhR signaling pathway has been 
shown to modulate tyrosine kinases associated with the epidermal growth factor receptor 
(EGFR) and Akt/PKB (Marlowe & Puga, 2005). Therefore, the biological effects of the 
AhR could occur via at least two general mechanisms: direct influence on gene 
transcription by binding to DRE motifs and/or modulation of signaling pathways by 
protein–protein interaction (Suh et al., 2002). 
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Figure 29. Chromatograph showing the three SNPs location in the transactivation 
domain of the CL-01 AhR exon 10. The heterozygous SNPs are shown in three positions 
with two overlap peaks. Each peak represents a nucleotide with a coded color: green for 
Adenine; red for Thymine; black for Guanine and blue for Cytosine (Kashgari 2015, 
unpublished data). 
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 Although the Src protein kinase is associated with the AhR complex in the cytosol 
(Enan & Matsumura, 1996), phospho-Src was not in the CL-01 cells with or without 
stimulation. However, Src kinases are initially activated after BCR ligation by antigen. 
Therefore, signaling through the BCR could be the only pathway to activate Src; whereas, 
in these studies R848 stimulation was used, which activates the TLRs 7 and 8. Src 
activation may need a BCR ligand to increase B-cell activation and Ig production. 
Alternatively, the Src protein associated with the cytosolic AhR complex may only be 
released and activated by TCDD binding (Enan & Matsumura, 1996). In other words, 
binding of the AhRA may not induce the proper conformational change to release Src. 
Moreover, Western blot analysis may not be the most sensitive technique to detect 
phospho-Src. In a previous Src study, they used fluorescence resonance energy transfer 
(FRET) to visualize and quantify phosph-Src (Tyr416) (Dong et al., 2011).  
 The Akt protein kinase was also activated by the AhR signaling pathway in several 
human cells (Wu et al., 2007; Al-Dhfyan et al., 2017). The results showed that Akt is 
basally phosphorylated in CL-01 cells but after 30 minutes of AhRA treatment, Akt 
phosphorylation significantly increased and at 2 hours returned to basal phosphorylation 
level. In another study using the mouse CH12.LX cell line, the most abundance of p-Akt 
was observed within the first 60 minutes after treating R848-stimulated cells with 0.3 nM 
TCDD but 30 nM TCDD significantly suppressed R848-activated phosphorylation of Akt 
protein, which is compatible with the suppression of Ig production by TCDD (North et al., 
2010). Additionally, Loss of the AhR lead to impaired activation of Akt and enhanced 
sensitivity to apoptosis in a hepatoma cell line (LA1) (Wu et al., 2007). Another study 
showed that the AhR signaling pathway controls proliferation and development of breast 
80 
 
cancer cells through activation of Akt pathways (Al-Dhfyan et al., 2017). These studies 
indicate that the cytosolic AhR can modulate the Akt pathway. Chemical antagonism of 
the AhR in the CL-01 cells appears to induce Akt phosphorylation, which may contribute 
to the increase in IgG secretion. Upon phosphorylation of Akt, the Akt signaling pathway 
mediates multiple downstream events. Phosphorylated Akt activates the mTOR complex, 
causing increased mRNA translation, protein synthesis and cellular proliferation (Agata et 
al., 2010). Phosphorylated Akt enters the nucleus to inactivate forkhead box O (FOXO) 
protein, which blocks cell cycle progression and promotes stress resistance, which help in 
B-cell proliferation (Limon & Fruman, 2012). Moreover, Akt phosphorylation induces 
activation of IKKα leading to dissociate NFκB from IκB and increase the NFκB 
transcription activity (Liou et al., 1994).  
  The NFκB has an important role in B-cell activation, activity of the mouse 3’IghRR, 
and the AhR physically interacts with NFκB (Tian et al., 1999). In human, the invariant 
sequence in the hs1.2 enhancer of the 3’IHGRR contains DRE, NFκB, SP-1, NF-1 and AP-
1 binding sites (Pinaud et al., 2011). Two separate pathways can activate NFκB; the 
“canonical” pathway is triggered by TLR, TNFα and IL-1, and the “alternative” pathway 
is activated by CD40L, BAFF and lymphotoxin (Lawrence, 2009). The AhRA could 
influence interaction of AhR with any protein in these two pathways that lead to increase 
Ig expression. Previous studies in our lab has shown that stimulation with R848, a synthetic 
molecule that activates B cells via the TLR7/8, or with CD40L plus IL4 increased IgG 
production (Burra 2015, unpublished data). Both methods of stimulation activate either 
canonical or alternative NFκB activation pathways (Hanten et al., 2008; Lawrence, 2009), 
which suggests that activation of NFκB transcription factors could influence IgG 
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production. Our results showed that the R848 stimulation significantly increased the NFκB 
plasmid activity but TCDD and AhRA have no effect on NFκB activity. As mentioned, 
Akt signaling pathway activates NFκB and this activity should be increased with cells 
treated with AhRA because AhRA increase the Akt activity. But the result showed that 
NFκB reporter activity was not affected by AhRA. The Akt activates other signaling 
pathway like mTOR or FOXO but not NFκB pathway, or Akt may increase the translation 
of NFκB but not transcription activity. In addition, the NFκB reporter may not reflect the 
complexity of protein-protein interactions and transcriptional regulation that may vary 
from gene to gene. 
 The AP-1 is another transcription factor binding site in the hs1.2 enhancer of the 
3’IGHRR (Pinaud et al., 2011). The results suggests that AP-1 has no role in increased IgG 
production by AhRA and therefore, the AhRA may not influence an AhR interaction with 
AP-1 pathway proteins like c-Fos or c-Jun. Furthermore, R848 stimulation lowered AP-1 
suggesting that activation of the TLR7/8 signaling pathway inhibits AP-1 transcriptional 
activity. Another possibility is that the CL-01 cells were isolated from a Burkett’s 
lymphoma patient. In Birkett’s lymphoma, the B cell lymphoma-6 (BCL-6) gene is 
involved in chromosomal translocation that could lead to sustained expression of BCL-6. 
The BCL-6 encodes a transcriptional repressor protein that is expressed in B cells in the 
germinal center reaction and is down-regulated upon B cell differentiation into plasma cells 
(Vasanwala et al.,2002). TLR stimulation of CL-01 cells may activate the BCL-6 that binds 
to c-Jun and disrupts dimerization of c-Jun leading to repression of AP-1 activity and 
inhibit B cell differentiation (Vasanwala et al.,2002). Previous studies in our lab showed 
that both R848 and CD40L plus IL-4 stimulation inhibited the basal activity of the hs1.2 
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and hs3-1.2 enhancers, which has the intervening sequences between hs3 and hs1.2, 
reporters activity (Freiwan, 2014; Alfaheeda, 2016 unpublished data) suggesting that AP-
1 may have a positive regulator role in the transcriptional activity of the 3’IGHRR 
enhancers in human CL-01 cells stimulated with either R848 or CD40L plus IL-4. 
 The human and mouse AhR gene have single nucleotide polymorphisms (SNPs) in 
different locations and they only share about 58% amino acid sequence in the C-terminal 
of the gene that includes the transactivation domain (Flaveny et al. 2008). As mentioned, 
CL-01 human B cells have a heterozygous AhR, likely with a non-functional 
transactivation domain in one of its alleles due to the identification of three SNPs (Fig. 29) 
(Kashgari 2015, unpublished data). These SNPs could be the reason why the human 
3’IGHRR is more sensitive to TCDD in a mouse B-cell line that expresses a highly 
functional AhR signaling pathway compared to the human (Alfaheeda 2016, unpublished 
data). Using an AhR with a functional transactivation domain (AhR TA) (Panstingel 2017, 
unpublished data), TCDD induced the DRE reporter activity unlike the CL-01 WT cells 
suggesting that these CL-01 WT cells may express a dominant negative AhR. The 
dysfunction of the AhR transactivation domain in the CL-01 wild type had no effect on the 
sensitivity of the 3’IGHRR to TCDD or AhRA since it has the same effects as in CL-01 
cells expressing only an AhR with a functional transactivation domain. Moreover, 
Increases in the Iγ3-3’IGHRR reporter activity is compatible with previous results that 
AhRA increased the secretion of IgG (Burra 2015, unpublished data) supporting that the 
cytosolic AhR induces a non-genomic effect perhaps by interacting with signaling proteins 
leading to an increase in IgG secretion and Iγ3-3’IGHRR activity. In addition, TCDD has 
no effect on the 3’IGHRR reporter activity may results of the TCDD induces multiple 
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interaction of the AhR with different proteins. TCDD induces the crosstalk between AhR 
and many signaling pathways like Src, Akt/PKB, NFκB and Wnt/β-catenin (Suh et al., 
2002; Wu et al., 2007; Enan and Matsumura, 1996; Tian et al., 1999) therefore, the non-
genomic interaction of the AhR with other proteins may consume the AhR proteins and 
decrease nuclear translocation of the AhR. 
 Previous studies on mouse B cells showed that the AhR mediates TCDD-induced 
inhibition of Ig and B-cell differentiation (Wourms & Sulentic, 2015; Vorderstrasse et al., 
2001). Moreover, AhR knockdown by shRNA or inhibition by an AhR antagonist reversed 
TCDD-induced inhibition of IgA secretion but did not alter basal or stimulation-induced 
IgA secretion in CH12.LX cells (Wourms & Sulentic, 2015). Another study with AhR-/- 
mice showed normal immune function and Ig production after treatment with TCDD 
(Vorderstrasse et al., 2001). These provide evidence that the AhR mediates TCDD-induced 
inhibition of Ig and B-cell differentiation but it is not required for normal immune function 
(Wourms & Sulentic, 2015; Vorderstrasse et al., 2001). However, in a human B-cell line, 
IgG secretion was inhibited by TCDD and surprisingly increased by AhRA. Moreover, 
TCDD inhibited the induction of Cγ1-4 germline/functional transcripts while the AhRA 
alone increased all of the Cγ1-4 germline/functional transcripts (Burra 2015, unpublished 
data).Our lab has also used shRNA to target and degrade AhR mRNA and knockdown the 
AhR protein levels. IgM secretion was unaffected by AhR knockdown, whereas IgG levels 
were nearly eliminated with AhR knockdown (Kashgari 2015, unpublished data). These 
observations match with our results for AhR knockdown (KD) using the CRISPR/Cas9 
gene editing. The AhR KD clone inhibited IgG secretion as previously seen with AhR 
knockdown by shRNA suggesting a physiological role of the AhR in IgG expression. In 
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addition, the result suggests that the non-functional transactivation domain of the AhR has 
no effect on IgG production. CRISPR/Cas9 clones that have edited the nonfunctional AhR 
transactivation domain (TA) allele appeared to change in the expression level of the AhR 
over time. Suggesting the functional AhR TA allele, which not edited by CRISPR/Cas9, 
appears to compensate for the decrease in AhR expression and returns it to normal 
expression level. While the knockdown clone showed stable AhR knockdown suggesting, 
that CRISPR/Cas9 edited and disrupted both AhR alleles.  
 Although TCDD had no effect on Iγ3-3’IGHRR reporter activity in CL-01 WT, 
AhR TA and AhR KD clones, the AhRA increased Iγ3-3’IGHRR activity in CL-01 WT 
and AhR TA clones while it has no effect in the AhR KD clone. Indicating that TCDD has 
no effect on 3’IGHRR regardless of AhR expression or function while the AhRA could 
influence the interaction of the cytosolic AhR with signaling proteins leading to an increase 
in Iγ3-3’IGHRR activity that could increase IgG secretion supporting an AhR non-genomic 
effect and a physiological role of the AhR in the expression of IgG. Furthermore, the basal 
activity of the 3’IGHRR reporters in the AhR knockdown clone was lower than in the AhR-
expressing cells indicates the AhR mediated the basal activity of the 3’IGHRR reporters.  
 A limitation of using reporter plasmids is that they may not actually reflect enhancer 
activity in the context of chromatin. Additionally, the 3’IGHRR reporter constructs lack 
the intervening sequence between hs1.2 and hs4 enhancers because it is difficult to include 
in the reporter because of size. The current 3’IGHRR reporter contains about 10 kb while 
the intervening sequence between the hs1.2 and hs4 enhancers is about 10 kb. This 
intervening sequence may play a critical role in 3’IGHRR function since it contains 
transcription factor binding sites and has a unique repetitive nucleotide sequences that may 
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contribute to the secondary structures of the 3’IGHRR and may affect its function (Giambra 
et al., 2005). In addition, the 3’IGHRR reporter plasmids behave differently depending on 
if they are transfected into mouse or human B-cell lines. Previous work has shown that a 
plasmid containing just the human hs1.2 enhancer will show a decrease in activity in 
response to B-cell stimulation when transfected into human B cells, whereas in mouse B 
cells stimulation will increase its activity (Fernando et al., 2012; Freiwan 2014, 
unpublished data). Moreover, the 3’IGHRR reporters have only one of the two 3’IGHRRs 
and perhaps both work in concert for expressing some of the CH isotypes. We also had 
difficulty sequencing exon 1 and exon 2 of the AhR to determine the edits induced by 
CRISPR/Cas9. We have tried to amplify and sequence the exon 1 and exon 2 in order to 
confirm the CRISPR/Cas9 edit. We suspect that these areas are polymorphic, preventing 
primers based on a reference AhR gene from binding within the CL-01 AhR gene. Ongoing 
studies in our lab are tring to address this peoblem by using a method called rapid 
amplification of 5′ complementary DNA ends (5′ RACE) in order to sequence the exons 1 
and 2 of the AhR gene. This method is used to extend partial cDNA clones by amplifying 
the 5′ sequences of the corresponding mRNA. 
 In future studies, we should expand the signaling analysis to cover most of the B-
cell signaling pathways such as Ca2+, Syk pathways or transcription factors like SP1 and 
NFAT that could interact with AhR in order to understand the AhR role in IgG production. 
Studies should also focus on analysis of all Akt signaling pathways such as mTOR and 
FOXO pathways to define if AhRA has an effect on one of these pathways to mediate the 
increase IgG secretion. Measuring the Akt in the AhR knockdown clone could confirm the 
interaction of AhR with Akt protein. In addition, using gene editing like CRISPR/Cas9 
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technique to mutate or delete specific 3’IGHRR enhancers in order to determine the role 
of this enhancer in TCDD and AhRA effects. Moreover, a cell line with two 
transcriptionally function AhR alleles must be used to test the effect of TCDD on human 
3’IGHRR enhancers. Additionally, using different human B cell line with specific 
characteristics representing normal human B cells may provide better understanding for 
the human 3’IGHRR and the effect of TCDD on it. An ongoing work in our lab on another 
B cell line (U266), which is a human B cell line isolated from myeloma may add more 
knowledge about B cells sensitivity to TCDD in different stages of B cell development. 
 In conclusion, our results suggest that the AhRA nearly completely inhibits AhR 
translocation into the nucleus and TCDD reverses this inhibition. B cells have nuclear AhR 
that could be localized in the nucleus independent of ligand activation or an endogenous 
ligand may promote a low level of basal AhR activation. The AhR has non-genomic effects 
by activating cytosolic signaling protein like Akt and increasing the Iγ3-3’IGHRR reporter 
activity in response to AhRA that could lead to an increase in IgG secretion. Interestingly, 
the dysfunction of the AhR transactivation domain in the CL-01 wild type has no effect on 
the sensitivity of the 3’IGHRR to TCDD or AhRA suggesting that the AhRA is mediating 
non-genomic effects through the AhR. AhR knockdown by gene editing markedly 
inhibited IgG secretion, both basal and induced, and AhRA has no effect on Iγ3-3’IGHRR 
activity supporting an AhR non-genomic effect and a physiological role of the AhR in the 
expression of IgG. Significantly, understanding how the AhR-ligands modulate Ig 
expression and CSR and its relation to the 3’IGHRR will provide insight into how 
chemically-induced immunotoxic effects are mediated. The human 3’IGHRR has a 
polymorphism in the hs1.2 enhancer that has been associated with Burkitt’s lymphoma and 
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a number of autoimmune disorders such as celiac disease, psoriatic arthritis, IgA 
nephropathy, rheumatoid arthritis, systemic sclerosis, and plaque psoriasis. Consequently, 
determining the role of the 3’IGHRR and its potential difference in sensitivity to the AhR 
could provide new insight into potential environmental triggers of immune disorders and 
provide new targets for drug development. 
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